Juan Chipollini

Interests

No activities entered.

Courses

Scholarly Contributions

Chapters

• Chipollini, J. (2020). Management of Local, Regional, and Metastatic Penile Cancer. In Urologic Principles and Practice(pp 591-609). Springer. doi:10.1007/978-3-030-28599-9_36
• Chipollini, J., & Punnen, S. (2016). Salvage Cryoablation of the Prostate. In Prostate Cancer: Science and Clinical Practice, Second Edition(pp 543-549). doi:10.1016/B978-0-12-800077-9.00058-X
  More info

  Radiation therapy has been become a popular treatment option for the treatment of localized prostate cancer (PCa). Unfortunately, a number of patients fail treatment. Salvage radical prostatectomy has been the most established therapeutic option for locally recurrent PCa; however, the operation is technically difficult and not without significant morbidity. Salvage cryoablation has emerged as an increasingly popular minimally invasive alternative with comparable safety and efficacy profiles. In this chapter, we focus on recent oncological and functional outcomes, as well as patient selection and potential complications of salvage cryotherapy for radiorecurrent PCa.
• Chipollini, J., Henning, M., & Lokeshwar, V. (2016). Molecular Biomarkers and Treatments for Renal Cell Carcinoma. In Biomarkers in Disease: Methods, Discoveries and Applications. Biomarkers in Kidney Disease(pp 1015-1032). New York, NY: Springer. doi:10.1007/978-94-007-7699-9_47
• Tang, D., Chipollini, J., & Spiess, P. (2016). Disease in Penile Cancer. Urologic Oncology. In Advanced and Recurrent Disease. Philadelphia, PA.: Springer.

Journals/Publications

• Asif, W., Paster, I. C., Pulling, K. R., Garcia, K., Wightman, P., Cruz, A., Combates, C., Kauffman, E. C., Gachupin, F. C., Lee, B. R., Chipollini, J., & Batai, K. (2024). Differential effects of obesity on perioperative outcomes in renal cell carcinoma patients based on race and ethnicity and neighborhood-level socioeconomic status. Translational andrology and urology, 13(4), 548-559.
  More info

  Obesity is a well-established risk factor of renal cell carcinoma (RCC), however the impact of obesity on surgical outcomes for racial and ethnic minority patients with RCC is unclear. This study investigated whether a higher body mass index (BMI) or obesity (BMI ≥30 kg/m) was associated with worse perioperative outcomes and if there were heterogeneous effects based on race, ethnicity, and neighborhood-level socioeconomic factor.
• Ogbuji, V., Gomez, D. M., Paster, I. C., Irizarry, V. M., McCormick, K., Dennis, L. K., Recio-Boiles, A., & Chipollini, J. (2024). Global burden of penile cancer: A review of health disparities for a rare disease. Urology.
  More info

  We performed a narrative review evaluating the influence of race and socioeconomic status for penile cancer patients based on region. We found higher incidence in underdeveloped nations. Globally, HPV-associated tumors are more prevalent, particularly in areas with high HPV and HIV infection. Socioeconomic determinants exacerbated these disparities. Similarly, in the United States, disparities were notable among racial and ethnic groups, with black men having worse survival. Understanding sociodemographic differences may help mitigate disparities by improving access to care with targeted interventions including education on risk factors and HPV vaccination to reduce penile cancer burden in vulnerable parts of the world.
• Pautler, S. E., Cifuentes, E. M., Avila-Monteverde, E., Cordero, M., Fernandez, A., Chipollini, J., & Lee, B. R. (2024). Tuberous Sclerosis Complex (TSC) Identified by Genetic Testing After Histologic Diagnosis of Chromophobe Renal Cell Carcinoma. SeriesScience International, 2.
• Torres Irizarry, V. M., Paster, I. C., Ogbuji, V., Gomez, D. M., Mccormick, K., & Chipollini, J. (2024). Improving Quality of Life and Psychosocial Health for Penile Cancer Survivors: A Narrative Review. Cancers, 16(7).
  More info

  Treatment of penile cancer (PC) focuses on organ preservation, employing various surgical and non-surgical approaches. These interventions may lead to disfigurement, impacting patients' functional outcomes and psychosocial well-being. We reviewed studies related to penile health and PC up to February 2024, limited to studies published in English. Studies employing health-related quality of life (HRQoL) assessments have identified a detrimental association between aggressive treatment and overall health status, physical functioning, and relationships. In contrast, organ-sparing demonstrates improved measures related to HRQoL and sexual function. Assessment through validated questionnaires reveals diverse voiding outcomes, and varying impacts on QoL and sexual activity, emphasizing the necessity for multidisciplinary personalized care. Studies highlight substantial variations in sexual function, with patients reporting adaptations, reduced satisfaction, and concerns about body image and sexual well-being. Furthermore, unmet needs include challenges in patient-clinician communication, obtaining information, and accessing psychosocial support. Patient experiences underscore the importance of timely diagnosis, treatment access, and addressing psychological consequences. Organ-sparing approaches have higher QoL preservation and sexual function. Individualized support, including sexual therapy, support groups, and family counseling, is essential for post-treatment rehabilitation. Timely diagnosis and comprehensive care are paramount in addressing the multifaceted impact of PC on patients and families.
• Valencia, C. I., Wightman, P., Morrill, K. E., Hsu, C. H., Arif-Tiwari, H., Kauffman, E., Gachupin, F. C., Chipollini, J., Lee, B. R., Garcia, D. O., & Batai, K. (2024). Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona. Cancer medicine, 13(3), e7007.
  More info

  Hispanics and American Indians (AI) have high kidney cancer incidence and mortality rates in Arizona. This study assessed: (1) whether racial and ethnic minority patients and patients from neighborhoods with high social vulnerability index (SVI) experience a longer time to surgery after clinical diagnosis, and (2) whether time to surgery, race and ethnicity, and SVI are associated with upstaging to pT3/pT4, disease-free survival (DFS), and overall survival (OS).
• Batai, K., Bertolo, A., Boiles, A. R., Chipollini, J., Dhaliwal, A., Estrada-Mendizabal, R. J., Heimark, R., Roe, D., Saboda, K., & Taylor, M. K. (2023).

  Genomic profiling between Hispanic Americans (HA) and non-Hispanic (NHW) with advanced prostate cancer: A retrospective analysis of tissue, liquid, and germline testing.

  . Journal of Clinical Oncology, 41(6_suppl), 30-30. doi:10.1200/jco.2023.41.6_suppl.30
  More info

  30 Background: Genomic testing through the employment of somatic and germline testing has become increasingly relevant in determining the prognosis and targeted therapies for advanced prostate cancer patients. Prostate cancer health disparities resulting in worse presentations and clinical outcomes have been observed in HA compared to NHW. Understanding the prevalence of different genomic alterations is paramount to bridge the gap between the two ethnic groups. Methods: This is a retrospective analysis of 190 metastatic prostate adenocarcinoma patients with 24.2% HA who presented to the University of Arizona Cancer Center from 2015 to 2022. Patients in both groups may have undergone more than one type of testing. Homologous recombination repair (HRR) included ATM, BRCA1/2, BARD1, BRIP1, CDK12, CHEK1/2, FANCA/L, HDAC2, PALB2, RAD-51B/1C/51D, or 54L. Tissue-agnostic therapy approvals are dMMR, MSI-H, TMB-High, BRAF V600E, and NTRK/RET fusion. The proportion of HA and NHW was determined, and the statistical significance of the differences was reported using Chi 2 or Fisher’s Exact test. Results: 43.6%, 34.7%, and 38.9% of patients had somatic tissue, liquid, and germline testing, respectively analyzed for pathogenic variants. TMB-High >10 (30% vs 3.6%, p=0.02), PD-L1 CPS>5 (9.4% vs 0%, p=0.03) and TMPRSS2-ERG fusion (37.5 vs 7.8%, p=0.0009) had higher proportion in HA compared to NHW. No test showed a difference in BRCA 1/2 or another HRR deficiency actionable mutation between the two ethnicities. There were no other statistically significant differences in common mutations or variants of unknown significance among groups. Conclusions: Liquid and tissue biopsies indicated a difference in proportions for tissue-agnostic and immune-oncology therapeutic indications, being more prevalent in HA. TMPRSS2-ERG fusions have differences in PC development and progression by race and now potentially by ethnicity, as shown by our study. Our review revealed increased germline and somatic testing over time according to targeted therapies approval and guideline recommendations, although, there remains a critical need for advancing genomic sequencing efforts for underrepresented HA. The Hispanic Americans Prostate Cancer Comprehensive Genomic Profiling Study's (THAPCA-GPS) future investigations aim to delineate the pathogenetic differences between HA and NHW and may reduce healthcare disparities and improve clinical outcomes in HA patients. [Table: see text]
• Carew, J. S., Chipollini, J., Espitia, C. M., Jones, T. M., Lee, B. R., Nawrocki, S. T., & Wertheim, J. A. (2023).

  Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity

  . Cancer Research Communications, 3(2), 245-257. doi:10.1158/2767-9764.crc-22-0340
• Chipollini, J., Hsu, C., Gachupin, F. C., Valencia, C. I., Wightman, P., Batai, K., Asif, W., Cruz, A., & Lee, B. R. (2023). Abstract C085: Intersectionality of neighborhood socioeconomic deprivation, race/ethnicity, and obesity in renal cell carcinoma disparities in Hispanics and American Indians in Arizona. Cancer Epidemiology, Biomarkers & Prevention, 32(1_Supplement), C085-C085. doi:10.1158/1538-7755.disp22-c085
• Estrada-Mendizabal, R. J., Dhaliwal, A. S., Bertolo, A. J., Batai, K., Heimark, R., Recio-Boiles, A., & Chipollini, J. (2023). Prostate Cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National Cancer Database. Clinical genitourinary cancer.
  More info

  Among Hispanic-American (HA) men, prostatic cancer (PCa) accounts for nearly one-quarter of the total cancer burden. We sought to identify differences in PCa presentation and treatment status for HA subgroups based on country/region of origin.
• Huelster, H. L., Chang, A., Rose, K., Bandini, M., Albersen, M., Roussel, E., Chipollini, J., Zhu, Y., Ye, D. W., Ornellas, A. A., Catanzaro, M., Marandino, L., Pederzoli, F., Hakenberg, O. W., Heidenreich, A., Haidl, F., Watkin, N., Ager, M., Ahmed, M. E., , Karnes, J. R., et al. (2023). Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?. The Journal of urology, 101097JU0000000000003099.
  More info

  Inguinal lymph node dissection within 3 months of primary tumor resection in penile cancer has been associated with longer recurrence-free and cancer-specific survival. However, the optimal timing and effect of lymphadenectomy performed concurrently at the time of primary lesion management on oncologic outcomes in clinically lymph node positive penile squamous cell carcinoma remains unknown.
• Jones, T. M., Espitia, C. M., Chipollini, J., Lee, B. R., Wertheim, J. A., Carew, J. S., & Nawrocki, S. T. (2023). Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity. Cancer research communications, 3(2), 245-257.
  More info

  Although cisplatin remains a backbone of standard-of-care chemotherapy regimens for a variety of malignancies, its use is often associated with severe dose-limiting toxicities (DLT). Notably, 30%-40% of patients treated with cisplatin-based regimens are forced to discontinue treatment after experiencing nephrotoxicity as a DLT. New approaches that simultaneously prevent renal toxicity while improving therapeutic response have the potential to make a major clinical impact for patients with multiple forms of cancer. Here, we report that pevonedistat (MLN4924), a first-in-class NEDDylation inhibitor, alleviates nephrotoxicity and synergistically enhances the efficacy of cisplatin in head and neck squamous cell carcinoma (HNSCC) models. We demonstrate that pevonedistat protects normal kidney cells from injury while enhancing the anticancer activity of cisplatin through a thioredoxin-interacting protein (TXNIP)-mediated mechanism. Cotreatment with pevonedistat and cisplatin yielded dramatic HNSCC tumor regression and long-term animal survival in 100% of treated mice. Importantly, the combination decreased nephrotoxicity induced by cisplatin monotherapy as evidenced by the blockade of kidney injury molecule-1 (KIM-1) and TXNIP expression, a reduction in collapsed glomeruli and necrotic cast formation, and inhibition of cisplatin-mediated animal weight loss. Inhibition of NEDDylation represents a novel strategy to prevent cisplatin-induced nephrotoxicity while simultaneously enhancing its anticancer activity through a redox-mediated mechanism.
• Lee, B. R., Jones, T., Chipollini, J., Wertheim, J. A., Carew, J. S., & Nawrocki, S. (2023). Targeting NEDDylation is a novel strategy to attenuate cisplatin-induced nephrotoxicity. . American Association for Cancer Research.
• Ogbuji, V., Paster, I. C., Recio-Boiles, A., Carew, J. S., Nawrocki, S. T., & Chipollini, J. (2023). Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?. Cancers, 16(1).
  More info

  Urothelial carcinoma (UC) is the most common form of bladder cancer (BC) and is the variant with the most immunogenic response. This makes urothelial carcinoma an ideal candidate for immunotherapy with immune checkpoint inhibitors. Key immune checkpoint proteins PD-1 and CTLA-4 are frequently expressed on T-cells in urothelial carcinoma. The blockade of this immune checkpoint can lead to the reactivation of lymphocytes and augment the anti-tumor immune response. The only immune checkpoint inhibitors that are FDA-approved for metastatic urothelial carcinoma target the programmed death-1 receptor and its ligand (PD-1/PD-L1) axis. However, the overall response rate and progression-free survival rates of these agents are limited in this patient population. Therefore, there is a need to find further immune-bolstering treatment combinations that may positively impact survival for patients with advanced UC. In this review, the current immune checkpoint inhibition treatment landscape is explored with an emphasis on combination therapy in the form of PD-1/PD-L1 with CTLA-4 blockade. The investigation of the current literature on immune checkpoint inhibition found that preclinical data show a decrease in tumor volumes and size when PD-1/PD-L1 is blocked, and similar results were observed with CTLA-4 blockade. However, there are limited investigations evaluating the combination of CTLA-4 and PD-1/PD-L1 blockade. We anticipate this review to provide a foundation for a deeper experimental investigation into combination immune checkpoint inhibition therapy in metastatic urothelial carcinoma.
• Paster, I. C., & Chipollini, J. (2023). AUTHOR REPLY. Urology, 178, 113.
• Paster, I. C., Zeng, J., Recio-Boiles, A., & Chipollini, J. (2023). Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients. Urology, 178, 105-113.
  More info

  To evaluate trends and racial variations of pathologic complete response (CR) in patients with muscle-invasive bladder cancer undergoing cystectomy.
• Peng, J., Weng, Z., Zhang, C., Zhou, G., Lin, Y., Kołat, D., Chipollini, J., & Wu, W. (2023). Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization. Translational andrology and urology, 12(11), 1697-1707.
  More info

  Transcatheter bladder arterial chemoembolization (TACE) is an alternative treatment used to control bladder cancer (BC) with bleeding, especially in older adult patients with comorbidities. This retrospective observational study evaluated the effect and prognostic factors of transcatheter drug-eluting bead (DEB) embolization in patients with advanced BC.
• Zeng, J., & Chipollini, J. (2023). Clinical registries in upper tract urothelial carcinoma: commitment to collaboration. Translational andrology and urology, 12(7), 1043-1044.
• Zeng, J., Funk, J., Lee, B. R., Hsu, C. H., Messing, E. M., & Chipollini, J. (2023). Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era. Translational andrology and urology, 12(6), 960-966.
  More info

  To evaluate the safety profile and efficacy of intravesical gemcitabine as first-line adjuvant therapy for non-muscle invasive bladder cancer (NMIBC) in the setting of ongoing Bacillus Calmette-Guérin (BCG) shortage.
• Batai, K., Chipollini, J., Hsu, C., Gachupin, F. C., Cruz, A., Dickerson, F., Pulling, K. R., Garcia, K., & Lee, B. R. (2022). Abstract PO-169: Impacts of neighborhood characteristics and surgical treatment disparities on overall mortality in stage I renal cell carcinoma patients. Cancer Epidemiology, Biomarkers & Prevention, 31(1_Supplement), PO-169-PO-169. doi:10.1158/1538-7755.disp21-po-169
• Chipollini, J. (2022). Editorial Comment. Journal of Urology, 208(4), 894-895. doi:10.1097/ju.0000000000002788.01
• Chipollini, J. (2022). Editorial Comment. The Journal of urology, 207(1), 69.
• Chipollini, J. (2022). Editorial Comment. The Journal of urology, 208(4), 894-895.
• Cruz, A., Dickerson, F., Pulling, K. R., Garcia, K., Gachupin, F. C., Hsu, C. H., Chipollini, J., Lee, B. R., & Batai, K. (2022). Impacts of Neighborhood Characteristics and Surgical Treatment Disparities on Overall Mortality in Stage I Renal Cell Carcinoma Patients. International journal of environmental research and public health, 19(4).
  More info

  Racial/ethnic minority groups in the United States have high renal cell carcinoma (RCC) mortality rates. This study assessed surgical treatment disparities across racial/ethnic groups and impacts of neighborhood socioeconomic characteristics on surgical treatments and overall mortality. Stage I RCC patients diagnosed between 2004 and 2016 from National Cancer Database were included (n = 238,141). We assessed differences in associations between race/ethnicity and treatment patterns using logistic regression and between race/ethnicity and overall mortality using Cox regression with and without neighborhood characteristics in the regression models. When compared to non-Hispanic Whites (NHWs), American Indians/Alaska Natives and non-Hispanic Blacks (NHBs) were more likely not to receive surgical care and all racial/ethnic minority groups had significantly increased odds of undergoing radical rather than partial nephrectomy, even after adjusting for neighborhood characteristics. Including surgical treatment and neighborhood factors in the models slightly attenuated the association, but NHBs had a significantly increased risk of overall mortality. NHBs who underwent radical nephrectomy had an increased risk of mortality (HR 1.15, 95% CI: 1.08-1.23), but not for NHBs who underwent partial nephrectomy (HR 0.92, 95% CI: 0.84-1.02). Neighborhood factors were associated with surgical treatment patterns and overall mortality in both NHBs and NHWs. Neighborhood socioeconomic factors may only partly explain RCC disparities.
• Gachupin, F. C., Lee, B. R., Chipollini, J., Pulling, K. R., Cruz, A., Wong, A. C., Valencia, C. I., Hsu, C. H., & Batai, K. (2022). Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona. International journal of environmental research and public health, 19(3).
  More info

  American Indians/Alaska Natives (AI/AN) and Hispanic Americans (HA) have higher kidney cancer incidence and mortality rates compared to non-Hispanic Whites (NHW). Herein, we describe the disparity in renal cell carcinoma (RCC) surgical treatment for AI/AN and HA and the potential association with mortality in Arizona. A total of 5111 stage I RCC cases diagnosed between 2007 and 2016 from the Arizona Cancer Registry were included. Statistical analyses were performed to test the association of race/ethnicity with surgical treatment pattern and overall mortality, adjusting for patients' demographic, healthcare access, and socioeconomic factors. AI/AN were diagnosed 6 years younger than NHW and were more likely to receive radical rather than partial nephrectomy (OR 1.49 95% CI: 1.07-2.07) compared to NHW. Mexican Americans had increased odds of not undergoing surgical treatment (OR 1.66, 95% CI: 1.08-2.53). Analysis showed that not undergoing surgical treatment and undergoing radical nephrectomy were statistically significantly associated with higher overall mortality (HR 1.82 95% CI: 1.21-2.76 and HR 1.59 95% CI: 1.30-1.95 respectively). Mexican Americans, particularly U.S.-born Mexican Americans, had an increased risk for overall mortality and RCC-specific mortality even after adjusting for neighborhood socioeconomic factors and surgical treatment patterns. Although statistically not significant after adjusting for neighborhood-level socioeconomic factors and surgical treatment patterns, AI/AN had an elevated risk of mortality.
• Heimark, R., Recio-boiles, A., Chipollini, J., Cheng, C., & Batai, K. (2022). Disparities in prostate cancer: An ethnicity comparative focus among Hispanic Americans versus non-Hispanic whites.. Journal of Clinical Oncology, 40(6_suppl), 23-23. doi:10.1200/jco.2022.40.6_suppl.023
  More info

  23 Background: Prostate cancer (PCa) is a clinically heterogeneous disease and the incidence and mortality risk varies widely among racial/ethnic groups. Among Hispanic American (HA) men, PCa accounts for nearly one-quarter of the total cancer burden; in addition, advanced stage and mortality rates are significantly higher in HA compared to Non-Hispanic White (NHW) men. Despite a decade of declining overall incidence rates, incidence rates of advanced PCa appear to be increasing over time among HA men, a similar pattern seen among Non-Hispanic Blacks (NHB). Methods: Using the National Cancer Database, we identified patients with histologically confirmed prostate adenocarcinoma with reported race/ethnicity, clinical staging, Gleason score ≥ 6, and PSA at diagnosis between 2010 and 2016. HAs were divided into four major subgroups: Mexican/Chicano, Puerto Ricans, Cubans, and Central/South Americans. NHB, Asian, and other racial groups were excluded. Statistical analysis was derived from the Kruskal-Wallis test for continuous variables and χ2 test for categorical variables. Univariable and multivariable logistic regression models were used to evaluate the association of HA ethnic subgroups with metastatic presentation and primary treatment. Results: A total of 428,829 patients were included with 5,625 (1.3%) being HA. Mexican comprised 51.2% of HAs and presented with higher PSA and Gleason score at diagnosis and more advanced cT, N1 and M1 stage when compared to NHW men and other HA subgroups (all, p < 0.001) (Table). After adjusting for age, PSA, year of diagnosis, cT, N, insurance, income, education, and performance score, Mexican had 1.32 (95%CI: 1.07-1.63, p = 0.01) higher odds of initial metastatic presentation and 0.68 (95%CI: 0.55-0.85, p < 0.001) lower odds of receiving treatment compared to NHW men while no statistically significant difference was seen for the other HA subgroups. Conclusions: Even after accounting for socioeconomic disparities, Mexican men present with a more aggressive disease when compared to NHW and other HA subgroups. Our results warrant further investigations into potential biological factors affecting HA PCa as well as identifications of potential barriers to treatment for vulnerable populations.[Table: see text]
• Lee, B. R., Fernandez, A., Gonzalez, A., Avila-Monteverde, E., Chipollini, J., & Pautler, S. (2022). A Typical Progression Pattern after Pre-Docetaxel Abiraterone for Metastatic Prostate Cancer: Report of Two Cases. Clinical Oncology Journal, 3(1), 1-5.
• Paster, I. C., & Chipollini, J. (2022). Importance of Addressing the Psychosocial Impact of Penile Cancer on Patients and Their Families. Seminars in oncology nursing, 38(3), 151286.
  More info

  In this article we review the quality of life and the psychosocial and functional outcomes experienced by patients and their partners following penile cancer diagnosis and treatment.
• Pautler, S., Avila-Monteverde, E., Gonzalez, A., Fernandez, A., Chipollini, J., & Lee, B. R. (2022). A Typical Progression Pattern after Pre-Docetaxel Abiraterone for Metastatic Prostate Cancer: Report of Two Cases. Clinical Oncology Journal, 3(1).
• Zeng, J., Wong, A., Pollock, G., & Chipollini, J. (2022). Clinical evaluation of COVID-19/SARS-CoV-2 diagnostic testing in asymptomatic urology patients: implications for resumption of elective surgical care.. World journal of urology, 40(1), 291-292.
• A S Johnstone, P., de Vries, H. M., Chipollini, J., Daniel Grass, G., Boyd, F., Korkes, F., Albersen, M., Roussel, E., Zhu, Y., Ye, D. W., Master, V., Le, T. L., Muneer, A., Brouwer, O. R., & Spiess, P. E. (2021). Impact of radiation therapy on perineal urethrostomy for penile cancer. Clinical and translational radiation oncology, 30, 84-87.
  More info

  A lack of demonstrated clinical benefit precludes radiotherapy (RT) from being recommended for pN1/pN2 penile cancer (PeCa) lesions; but it may be recommended in case of extranodal (pN3) disease or for positive resection margins. Perineal urethrostomy (PU) is a technique of urinary diversion in patients with PeCa requiring total or subtotal penectomy as primary therapy. Prior studies suggest PU failure rates of up to 30%, without specific mention of the potential role of RT. When RT is delivered for PeCa it is usually to the pre-pubic fat, groin and lateral pelvis, and not to the region of the PU. Here we describe the role of perioperative RT in a large, multi-institutional registry of PU for PeCa.
• Bergersen, A. M., Khan, I., Wong, A. C., Chipollini, J. J., Weiss, B. D., & Tzou, D. T. (2021). Reply by Authors. Urology practice, 8(2), 252.
• Brucks, E., Chipollini, J., Saboda, K., Mcbride, A., Dashkevych, U., Chipollini, J., Boiles, A. R., & Babiker, H. M. (2021). A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).. Journal of Clinical Oncology, 39(6_suppl), 410-410. doi:10.1200/jco.2021.39.6_suppl.410
  More info

  410Background: MB is a serious complication in patients with CAVTE receiving treatment with DOAC or LMWH. The most recent meta-analysis of the four major RCT showed that MB events rate were similar...
• Chipollini, J. (2021). Editorial Comment. Journal of Urology, 206(2), 362-362. doi:10.1097/ju.0000000000001775.01
• Chipollini, J. (2021). Editorial Comment. The Journal of urology, 101097JU000000000000177501.
• Chipollini, J., Pollock, G., Hsu, C. H., Batai, K., Recio-Boiles, A., & Lee, B. R. (2021). National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status. Cancer medicine, 10(21), 7466-7474.
  More info

  There are no series evaluating penile squamous cell carcinoma (pSCC) based on human papillomavirus (HPV) infection. Herein, we present national registry data on clinical and survival outcomes for pSCC based on HPV status.
• Gelmann, E. P., Recio-boiles, A., Mcbride, A., Chipollini, J., Chineke, I. G., & Cheng, C. (2021). Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.. Journal of Clinical Oncology, 39(15_suppl), e16506-e16506. doi:10.1200/jco.2021.39.15_suppl.e16506
  More info

  e16506 Background: ICI have proven to benefit patients diagnosed with aUC who are platinum-ineligible. The role of platinum-eligible patients, in the first-line setting is being further elucidated after single positive randomized clinical trial (RCT) with ICI. Hence, we performed a meta-analysis to interpret the association of Overall Survival (OS) and PD-1 or PD-L1 inhibitors as first-line therapies in platinum-eligible patients with aUC. Methods: Randomized controlled trials were retrieved from PubMed, Web of Science, and Cochrane Library according to established inclusion criteria. Each article was assessed by the Newcastle-Ottawa Scale. The Hazard Risk (HR) and 95% confidence intervals (CI) were calculated. Random effect or fixed-effect model was used to calculate the pooled HR, based on heterogeneity significance. Sensitivity analysis and publication bias detection were performed. All statistical analysis were performed using RevMan software (v5.4; Cochrane library) and R Core Team (2016, Vienna, Austria), and all p-values were two-tailed, and the significance level was 0.05. Results: Sixty-seven articles were obtained from the database search, and based on inclusion/exclusion criteria, five RCTs were selected involving 4063 patients. All studies were considered moderate to high quality. A statistically significant association was found between initiation of immunotherapy as first-line treatment to platinum-eligible patients and increased OS (HR 0.87; 95% CI: 0.81,0.94, p = 0.004, I2= 38%). The subgroup analysis included positive PD1 (HR 0.81; 95% CI: 0.70,0.94, p = 0.004, I2= 34%) vs. negative expression (HR 0.96; 95% CI: 0.83,1.11, p = 0.58, I2= 0%); cisplatin (HR 0.81; 95% CI: 0.69,0.96, p = 0.02, I2= 47%) vs. carboplatin administration (HR 0.87; 95% CI: 0.76,1.01, p = 0.06, I2= 21%); male (HR 0.87; 95% CI: 0.77,0.97, p = 0.01, I2= 44%) vs. female (HR 0.85; 95% CI: 0.70,1.04, p = 0.11, I2= 0%); ECOG score 0 (HR 0.77; 95% CI: 0.67,0.89, p = 0.0005, I2= 0%) vs. ≥ 1 (HR 0.90; 95% CI: 0.78,1.02, p = 0.11, I2= 6%); Caucasian (HR 0.81; 95% CI: 0.73, 0.91, p = 0.0003, I2= 39%) vs. other race (HR 0.92; 95% CI: 0.75, 1.13, p = 0.44, I2= 0%). Similar association regardless of visceral lesion or age. Funnel plot, Egger's test (p = 0.6944), and Begg's test (0.7726) found no publication bias of analysis. Conclusions: This meta-analysis showed improved OS in platinum-eligible patients receiving first-line ICI in aUC. Furthermore, a subgroup analysis yielded an increased OS and cisplatin, positive PD1 status, ECOG 0, male gender, and Caucasian race. In this rapidly evolving clinical practice changes, our meta-analysis provides support to currently recommended avelumab maintenance after platinum induction therapy in the first-line setting and further provide guidance on patient selection for aUC.
• Pollock, G., Hsu, C. H., Batai, K., Lee, B. R., & Chipollini, J. (2021). Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma. Urology.
  More info

  To analyze utilization and outcomes of cytoreductive surgery (CRS) after systemic chemotherapy in select patients with metastatic upper tract urothelial carcinoma (UTUC).
• Quinonez-Zanabria, E., Valencia, C. I., Asif, W., Zeng, J., Wong, A. C., Cruz, A., Chipollini, J., Lee, B. R., Gachupin, F. C., Hsu, C. H., & Batai, K. (2021). Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics. Healthcare (Basel, Switzerland), 9(9).
  More info

  Racial/ethnic minority groups have a disproportionate burden of kidney cancer. The objective of this study was to assess if race/ethnicity was associated with a longer surgical wait time (SWT) and upstaging in the pre-COVID-19 pandemic time with a special focus on Hispanic Americans (HAs) and American Indian/Alaska Natives (AIs/ANs). Medical records of renal cell carcinoma (RCC) patients who underwent nephrectomy between 2010 and 2020 were retrospectively reviewed ( = 489). Patients with a prior cancer diagnosis were excluded. SWT was defined as the date of diagnostic imaging examination to date of nephrectomy. Out of a total of 363 patients included, 34.2% were HAs and 8.3% were AIs/ANs. While 49.2% of HA patients experienced a longer SWT (≥90 days), 36.1% of Non-Hispanic White (NHW) patients experienced a longer SWT. Longer SWT had no statistically significant impact on tumor characteristics. Patients with public insurance coverage had increased odds of longer SWT (OR 2.89, 95% CI: 1.53-5.45). Public insurance coverage represented 66.1% HA and 70.0% AIs/ANs compared to 56.7% in NHWs. Compared to NHWs, HAs had higher odds for longer SWT in patients with early-stage RCC (OR, 2.38; 95% CI: 1.25-4.53). HAs (OR 2.24, 95% CI: 1.07-4.66) and AIs/ANs (OR 3.79, 95% CI: 1.32-10.88) had greater odds of upstaging compared to NHWs. While a delay in surgical care for early-stage RCC is safe in a general population, it may negatively impact high-risk populations, such as HAs who have a prolonged SWT or choose active surveillance.
• Tzou, D. T., Tzou, D. T., Chipollini, J. J., Wong, A. C., Weiss, B. D., Khan, I., Chipollini, J. J., & Bergersen, A. M. (2021). Online Kidney Stone Educational Materials Do Not Meet Recommended Readability Standards. Urology Practice, 8(2), 246-252. doi:10.1097/upj.0000000000000183
  More info

  AbstractIntroduction:The prevalence of kidney stones is rising and there is an increasing demand for reliable, easy to understand information for patients. To evaluate the readability of common Int...
• Tzou, D. T., Weiss, B. D., Wong, A. C., Khan, I., Chipollini, J. J., & Bergersen, A. M. (2021). Reply by Authors. Urology Practice, 8(2), 252-252. doi:10.1097/upj.0000000000000183.04
• Valencia, C. I., Asmar, S., Hsu, C. H., Gachupin, F. C., Wong, A. C., Chipollini, J., Lee, B. R., & Batai, K. (2021). Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data. Cancers, 13(5).
  More info

  Renal cell carcinoma (RCC) is one of the top 10 cancers in the United States. This study assessed RCC health disparities in American Indians/Alaska Natives (AIs/ANs) and Hispanic Americans (HAs) focusing on advanced-stage and mortality. RCC patients' data were obtained from the National Cancer Database (NCDB) and Arizona Cancer Registry (ACR). Logistic and Cox regression analyses were performed to ascertain the effect of race/ethnicity on stage and mortality, adjusting for neighborhood socioeconomic factors, rural/urban residence pattern, and other factors. In both data sets, AIs/ANs had significantly increased odds of advanced-stage RCC in the unadjusted model, but not in adjusted models. Mexican Americans had higher odds of advanced-stage compared to non-Hispanic Whites in NCDB (OR 1.22, 95% CI: 1.11-1.35) and ACR (OR 2.02, 95% CI: 1.58-2.58), even after adjusting for neighborhood characteristics. AIs/ANs did not show increased mortality risk in NCDB after adjusting for neighborhood characteristics, while the association remained significant in ACR (HR 1.33, 95% CI: 1.03-1.72). The great risk of all-cause and RCC-specific mortality was observed in U.S.-born Mexican Americans in Arizona (HR 3.21, 95% CI: 2.61-3.98 and sub-distribution HR 2.79, 95% CI: 2.05-3.81). RCC disparities in AIs/ANs is partially explained by neighborhood factors, but not in HAs.
• Watkin, N., Vries, L. D., Vanthoor, J., Sri, D., Spiess, P. E., Sangar, V. K., Roussel, E., Peeters, E., Parnham, A., Muneer, A., Lau, M., Joice, G., Hatzichristodoulou, G., Chipollini, J., Brouwer, O. R., Bozzini, G., Bivalacqua, T. J., Bhattar, R., Ayres, B., & Albersen, M. (2021). Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma?. BJU international, 127(5), 606-613. doi:10.1111/bju.15297
  More info

  To identify predictive pathological factors for local recurrence (LR) and to study the impact of LR on survival in patients treated with glansectomy for penile squamous cell carcinoma (pSCC)..We retrospectively studied patients treated with glansectomy at international, high-volume reference centres. We analysed histopathological predictors of LR, stratified patients into risk groups based on the number of risk factors present, and studied the impact of LR on survival outcomes using Kaplan-Meier survival analysis and stepwise Cox proportional hazards regression models. Subsequently, we performed sensitivity analyses excluding margin-positive cases, pT3 disease, and cN+ disease, or all of these factors..Across nine institutions, 897 patients were included, of whom 94 experienced LR. On multivariable analysis, presence of high-grade disease and pT3 stage were independent predictors of LR. LR-free survival rates significantly differed according to the number of risk factors present, with a hazard ratio (HR) of 1.90 (95% confidence interval [CI] 1.17-3.07; P = 0.01) for the intermediate-risk group (one risk factor) and 6.11 (95% CI 3.47-10.77; P < 0.001) for the high-risk group (two risk factors), using the low-risk group (no risk factors) as reference. Patients who experienced LR had significantly worse overall survival (OS; HR 2.89, 95% CI 2.02-4.14; P < 0.001) and cancer-specific survival (CSS; HR 5.64, 95% CI 3.45-9.22; P < 0.001). LR (HR 3.82, 95% CI 2.14-6.8; P < 0.001), lymphovascular invasion and cN status were significant predictors of decreased CSS. LR remained a strong predictor of both OS and CSS in all sensitivity analyses..Pathological T3 stage and presence of high-grade disease were independent histopathological predictors of LR after glansectomy for primary pSCC, which allowed risk stratification into three groups with significantly different risk of developing LR. Additionally, LR is related to poor OS and CSS, indicating that LR is a manifestation of underlying aggressive disease and clearly challenging the dogma of using organ-sparing surgery whenever possible since survival is unaffected by higher LR rates.
• Wong, A. C., Quinonez-zanabria, E., Lee, B. R., Hsu, C., Gachupin, F. C., Cruz, A., Chipollini, J., Batai, K., & Asif, W. (2021). MP45-15 IMPACT OF PREOPERATIVE WAIT TIME ON RENAL CELL CARCINOMA TUMOR CHARACTERISTICS AND RACIAL AND ETHNIC DISPARITIES. Journal of Urology, 206(Supplement 3). doi:10.1097/ju.0000000000002066.15
• Zeng, J., Pollock, G., Addams, J., Bracamonte, E., & Chipollini, J. (2021). Leiomyosarcoma of the scrotum: a case report and literature review. Translational andrology and urology, 10(3), 1342-1346.
  More info

  Leiomyosarcoma (LMS) is one of the most common forms of soft tissue sarcoma with approximately 2,500 cases per year in the United States. The symptoms LMS vary depending upon the location, size, and spread of the tumor. In early stages, it may not be associated with any obvious symptoms so diagnosis and treatment may be delayed. In some cases, it can grow quickly and behave aggressively. Most types of LMS occur in the abdomen or in the uterus; although, scrotal LMS can be a very rare presentation of the disease. Here we present our case of a large, ulcerated scrotal LMS originating from subcutaneous tissue but not invading spermatic cord or tunica. Radical orchiectomy with high ligation of spermatic cord was performed, and patient had an uneventful postoperative course. This disease entity remains rare in the literature, and warrants larger studies in order to better understand treatment and oncologic outcomes. When LMS is identified early and is removed by surgical excision, prognosis can be good and full recovery quite likely. When LMS is already large or has spread to other parts of the body, treatment is relatively more complex and the prognosis poor. Hence, prompt diagnosis and treatment of genitourinary LMS require prompt attention, referral to tertiary, referral center should be strongly considered.
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Meerleer, G. D., Marandino, L., Johnstone, P. A., Heidenreich, A., Hakenberg, O. W., Haidl, F., Grass, G. D., Giannatempo, P., Chipollini, J., Brouwer, O. R., , Briganti, A., et al. (2021). Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration.. European urology oncology, 4(1), 121-123. doi:10.1016/j.euo.2020.07.007
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Salvioni, R., Ross, J. S., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Meerleer, G. D., Marandino, L., Johnstone, P. A., Heidenreich, A., Hakenberg, O. W., Haidl, F., Grass, G. D., Giannatempo, P., , Chipollini, J., et al. (2021). Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma.. European urology oncology, 4(5), 802-810. doi:10.1016/j.euo.2020.10.011
  More info

  Data on the impact of human papillomavirus (HPV) infection status and outcomes for perioperative treatments for patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking..To analyze the benefit from perioperative radiotherapy (RT) for PSCC according to HPV infection status..In an international multicenter database of 1254 patients with PSCC who received inguinal lymph node dissection (ILND), 507 had suitable clinical information..ILND, with or without chemotherapy or RT for involved lymph nodes..Kaplan-Meier and restricted mean survival time (RMST) analyses for overall survival (OS) were performed for all patients and after propensity score-matching (PSM; n = 136), for which patient age, histology, type of penile surgical procedure, pathological tumor and nodal stage, ILND laterality, pelvic LND, and perioperative treatment were taken into account when assessing differences between HPV+ and HPV- patients. Finally, we looked at genomic alterations in PSCC using data from the Foundation Medicine database (n = 199) to characterize HPV+ PSCC..Patients with HPV+ PSCC (n = 86; 17%) had lower clinical N stage (p < 0.001) and inguinal lymph node metastasis density (p < 0.001). Perioperative RT was delivered in 49 patients (9.7%), with the vast majority receiving adjuvant RT (n = 40). HPV+ patients had similar median OS (p = 0.1) but longer RMST than HPV- patients at different time points. Nevertheless, HPV+ patients treated with perioperative RT exhibited longer median OS (p = 0.015) and longer RMST compared to HPV- patients. In the PSM cohorts, HPV+ status remained significantly associated with longer OS after RT. The HPV- PSCC group had a higher frequency of TP53 mutations compared to HPV+ PSCC (75% vs 15%; p < 0.001). The results are limited by the retrospective nature of the data..Perioperative RT was more effective in the HPV+ PSCC subgroup. Reasons for the enhanced radiosensitivity may be related to the lack of TP53 mutations..We analyzed data from a large multicenter database for patients with penile cancer who had received inguinal lymph node dissection, with or without chemotherapy or radiotherapy. We found that for tumors positive for human papillomavirus (HPV), use of radiotherapy resulted in prolonged survival compared to HPV-negative tumors. On the basis of these results we are inspired to design studies on the use of radiotherapy in HPV-selected patients.
• de Vries, H. M., Chipollini, J., Slongo, J., Boyd, F., Korkes, F., Albersen, M., Roussel, E., Zhu, Y., Ye, D. W., Master, V., Le, T. L., Johnstone, P. A., Muneer, A., Brouwer, O. R., & Spiess, P. E. (2021). Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience. Urologic oncology, 39(8), 500.e9-500.e13.
  More info

  Perineal urethrostomy (PU) is often the definitive form of urinary diversion in patients with locally-advanced or anatomically unfavorable penile cancer (PC) requiring total penectomy. Here, we report post-operative PU-related complications and PU stenosis rates after total penectomy with PU in a large multicenter cohort of PC patients.
• Alfano, M., Pederzoli, F., Bandini, M., & Necchi, A. (2020). The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al. Urologic oncology, 38(9), 693-694.
• Bandini, M., Albersen, M., Chipollini, J., Pederzoli, F., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O. W., Heidenreich, A., Raggi, D., Catanzaro, M., Haidl, F., Mazzone, E., Marandino, L., Briganti, A., Montorsi, F., Azizi, M., , Spiess, P. E., et al. (2020). Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. BJU international, 125(6), 867-875.
  More info

  To identify predictors of poor overall survival (OS) amongst patients with penile squamous cell carcinoma (pSCC) with clinical inguinal lymphadenopathy (cN+), in order to define the best candidates for neoadjuvant chemotherapy (NAC).
• Bandini, M., Ross, J. S., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ayres, B. A., Hakenberg, O. W., Heidenreich, A., Salvioni, R., Catanzaro, M., Raggi, D., Giannatempo, P., Marandino, L., Haidl, F., Pederzoli, F., Briganti, A., Montorsi, F., Chipollini, J., , Azizi, M., et al. (2020). Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. European urology oncology.
  More info

  Data on the impact of human papillomavirus (HPV) infection status and outcomes for perioperative treatments for patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking.
• Bandini, M., Spiess, P. E., Pederzoli, F., Marandino, L., Brouwer, O. R., Albersen, M., Roussel, E., de Vries, H. M., Chipollini, J., Zhu, Y., Ye, D. W., Ornellas, A. A., Catanzaro, M., Hakenberg, O. W., Heidenreich, A., Haidl, F., Watkin, N., Ager, M., Ahmed, M. E., , Karnes, J. R., et al. (2020). A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU international, 126(5), 577-585.
  More info

  To develop and externally validate a risk calculator for prediction of any cancer recurrence in patients with penile squamous cell carcinoma (pSCC) and inguinal lymph node metastases (ILNM), as to date no validated prognostic tool is available for patients with pSCC and ILNM.
• Bandini, M., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ayres, B., Hakenberg, O. W., Heidenreich, A., Raggi, D., Giannatempo, P., Marandino, L., Haidl, F., Pederzoli, F., Briganti, A., Montorsi, F., Chipollini, J., Azizi, M., De Meerleer, G., Brouwer, O. R., , Grass, G. D., et al. (2020). Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. European urology oncology.
• Bandini, M., Zhu, Y., Ye, D., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O. W., Heidenreich, A., Raggi, D., Catanzaro, M., Haidl, F., Pederzoli, F., Briganti, A., Montorsi, F., Chipollini, J., Azizi, M., Albersen, M., Spiess, P. E., Necchi, A., & Brouwer, O. R. (2020). Regression tree analysis to identify the best candidates for neoadjuvant chemotherapy (NAC) in patients with clinically lymph node-positive penile squamous cell carcinoma (PSCC).. Journal of Clinical Oncology, 38(6_suppl), 2-2. doi:10.1200/jco.2020.38.6_suppl.2
  More info

  2Background: PSCC patients (pts) with palpable inguinal lymph node (ILN) disease have a poor overall survival (OS). For them, use of neoadjuvant chemotherapy (NAC) is recommended in guidelines, but...
• Bandini, M., Zhu, Y., Ye, D., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O. W., Heidenreich, A., Raggi, D., Catanzaro, M., Marandino, L., Haidl, F., Montorsi, F., Chipollini, J., Azizi, M., Albersen, M., Salvioni, R., Spiess, P. E., Necchi, A., & Brouwer, O. R. (2020). Development of a risk calculator of recurrence in inguinal lymph node metastatic (ILNM) patients with surgically resected penile squamous cell carcinoma (PSCC).. Journal of Clinical Oncology, 38(6_suppl), 1-1. doi:10.1200/jco.2020.38.6_suppl.1
  More info

  1Background: ILNM PSCC patients (pts) have heterogeneous outcomes. We aimed to identify risk factors of early recurrence in order to optimize the selection of pts for adjuvant (adj) therapies (tx)....
• Batai, K., Batai*, K., Chipollini, J., Gachupin, F. C., Lee, B. R., & Pollock, G. R. (2020).

  MP50-04 ASSESSMENT OF RENAL CELL CARCINOMA SURGICAL DISPARITIES IN AMERICAN INDIANS AND HISPANIC AMERICANS

  . The Journal of Urology, 203, e752-e753. doi:10.1097/ju.0000000000000912.04
• Batai, K., Chipollini, J., Gachupin, F. C., Hsu, C. H., Lee, B. R., & Valencia, C. I. (2020).

  Abstract PO-165: Renal cell carcinoma health disparities in American Indians/Alaska Natives and Hispanic Americans

  . Cancer Epidemiology and Prevention Biomarkers, 29(12_Supplement), PO-165-PO-165. doi:10.1158/1538-7755.disp20-po-165
  More info

  Background: American Indians/Alaska Natives (AIs/ANs) and United States (U.S.)- born Hispanic Americans (HAs) have higher kidney cancer mortality rates compared to non-Hispanic Whites (NHWs). However, causes for the disparities have not been well understood. The aim of our study was to assess if socioeconomic factors and residence pattern (urban vs. rural) account for renal cell carcinoma (RCC) health disparities in AIs/ANs and HAs focusing on advanced stage (stage III/IV) diagnosis and survival. Methods: RCC patients diagnosed between 2004 and 2015 (n=405, 073) in National Cancer Database (NCDB) and between 2007 and 2016 (n=9,982) in Arizona Cancer Registry (ACR) were analyzed. Logistic regression and Cox regression analysis were performed to ascertain the effect of race/ethnicity on stage at diagnosis and overall survival adjusting for patient’s characteristics, including census tract socioeconomic status (SES), Rural-Urban Continuum Codes (RUCC), and other relevant factors. High school graduate rate, median income (or poverty rate), and unemployment rate was used to measure socioeconomic status. In ACR data, sub- distribution Cox proportional hazards regression was performed to study time to death due to RCC accounting for competing risks. Results: There were a total of 405,073 cases in NCDB and 9,982 cases in ACR. In both NCDB and ACR data, AIs/ANs had significantly increased odds of having advanced stage at diagnosis in unadjusted model (OR 1.20, 95% CI: 1.08-1.33 and OR 1.29, 95% CI: 1.06-1.56 respectively in NCDB and ACR), but the association was not significant after adjusting for patient’s characteristics. In both datasets, Mexican Americans had higher odds of having advanced stage diagnosis compared to NHWs (OR 1.22, 95% CI: 1.11-1.35 and OR 2.02, 95% CI: 1.58-2.58 respectively) even after adjusting for patient’s characteristics, including SES and RUCC. In ACR, advanced stage diagnosis was particularly common in U.S.-born Mexican Americans (49.1%) compared to NHWs (26.4%). AIs/ANs showed increased mortality risk in unadjusted model in both datasets (HR 1.10, 95% CI:1.01-1.20 and HR 1.20, 95% CI: 1.05-1.37 respectively in NCDB and ACR). The association was no longer significant in NCDB after adjusting for patient’s characteristics, while it remained significant in ACR (HR 1.33, 95% CI: 1.03-1.72). In Arizona, Mexican Americans had significantly higher risk of mortality compared to NHWs in both unadjusted and adjusted models (HR 2.46, 95% CI: 2.23-2.72 and HR 2.34, 95% CI: 1.93-2.90). The greatest risk of all-cause and RCC-specific mortality was observed in U.S.-born Mexican Americans (HR 3.21, 95% CI: 2.61-3.98 and sub- distribution HR 2.79, 95% CI: 2.05-3.81). Conclusion: RCC disparities in AIs/ANs is partially explained by neighborhood socioeconomic and residence characteristics, but the neighborhood characteristics did not affect the associations for HAs. Greater RCC health disparities were observed among Mexican Americans in Arizona than the national level. Citation Format: Celina I. Valencia, Francine C. Gachupin, Chiu-Hsieh Hsu, Juan Chipollini, Benjamin R. Lee, Ken Batai. Renal cell carcinoma health disparities in American Indians/Alaska Natives and Hispanic Americans [abstract]. In: Proceedings of the AACR Virtual Conference: Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2020 Oct 2-4. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(12 Suppl):Abstract nr PO-165.
• Bergersen, A., Bergersen*, A., Chipollini, J., Khan, I., Tzou, D. T., & Weiss, B. D. (2020).

  MP12-08 DECREASED READABILITY OF ONLINE KIDNEY STONE EDUCATIONAL MATERIALS

  . The Journal of Urology, 203(Supplement 4). doi:10.1097/ju.0000000000000832.08
  More info

  INTRODUCTION AND OBJECTIVE:Limited health literacy has been associated with worse health outcomes across multiple medical conditions, yet how this relates to patients with kidney stones has yet to ...
• Chipollini, J., & Pollock, G. R. (2020). National trends in the management of low-risk prostate cancer: analyzing the impact of Medicaid expansion in the United States. International urology and nephrology, 52(9), 1611-1615.
  More info

  To evaluate recent trends in the management of low-risk prostate cancer (PCa) and analyze differences in adoption of surveillance based on state Medicaid-expansion status in the United States (US).
• Chipollini, J., Azizi, M., Lo Vullo, S., Mariani, L., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O., Heidenreich, A., Raggi, D., Catanzaro, M., Ornellas, P., Salvioni, R., Cheriyan, S. K., Necchi, A., & Spiess, P. E. (2020). Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU international, 125(1), 82-88.
  More info

  To evaluate the prognostic impact of lymph node yield (LNY) on survival outcomes for penile squamous cell carcinoma (SCC).
• Chipollini, J., Hsu, C. H., & Lwin, A. A. (2020).

  Urothelial Carcinoma of the Renal Pelvis and Ureter: Does Location Make a Difference?

  . Clinical genitourinary cancer, 18(1), 45-49.e1. doi:10.1016/j.clgc.2019.10.023
  More info

  There is a paucity of data on outcomes of upper tract urothelial carcinoma (UTUC) arising from the renal pelvis (RPUC) versus UTUC arising from the ureter (UUC). The published literature is conflicting, and there is no consensus on patient prognosis based on disease location. The aim of this study is to compare clinical and survival outcomes based on location of primary tumor using a large national registry..The National Cancer Database was queried from 2010 to 2016 for patients with localized (cN0M0) UTUC. Patients were stratified based on location of tumor. Survival analysis was performed using Cox proportional hazard regression and inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves. We also performed exploratory analyses based on tumor stage..We identified 11,922 patients who underwent surgical treatment. The median follow-up was 32.1 months. Patients with RPUC presented with higher tumor stage and grade. Patients with UUC were treated with less radical nephroureterectomy (56.4% vs. 84.3%; P < .01). IPTW-adjusted Kaplan-Meier curves demonstrated higher median overall survival for RPUC versus UUC (71.1 vs. 66.8 months, respectively; P = .01). This benefit was consistent across tumor stage subgroups, reaching statistical significance in patients with T1 disease. On multivariable analysis, ureteral location of tumor was a predictor of worse survival..Patients with UUC were found to be treated with less radical surgery and to have worse survival than those with RPUC. These patients may suffer from poor initial staging and suboptimal treatments. Further studies are needed to evaluate potential biological differences of UTUC based on tumor location.
• Chipollini, J., Wright, J. R., Nwanosike, H., Kepler, C. Y., Batai, K., Lee, B. R., Spiess, P. E., Stewart, D. B., & Lamendella, R. (2020). Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study. Urologic oncology, 38(7), 615-621.
  More info

  The human microbiome has been linked to the development of several malignancies, but there is scarcity of data on the microbiome of bladder cancer patients. In this study, we analyzed microbial composition and diversity among patients with and without bladder cancer.
• Chipollini, J., da Costa, W. H., Werneck da Cunha, I., de Almeida E Paula, F., Guilherme O Salles, P., Azizi, M., Spiess, P. E., Abreu, D., & Zequi, S. C. (2020). Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Therapeutic advances in urology, 11, 1756287219882600.
  More info

  We aimed to evaluate the prognostic role of programmed-death receptor ligand (PD-L1) in a multinational cohort of patients with localized renal cell carcinoma (RCC).
• Ghahhari, J., Marchioni, M., Spiess, P. E., Chipollini, J. J., Nyirády, P., Varga, J., Ditonno, P., Boccasile, S., Primiceri, G., De Nunzio, C., Tema, G., Tubaro, A., Veccia, A., Antonelli, A., Musi, G., De Cobelli, O., Conti, A., Puliatti, S., Micali, S., , Álvarez-Maestro, M., et al. (2020). Radical penectomy, a compromise for life: results from the PECAD study. Translational andrology and urology, 9(3), 1306-1313.
  More info

  The use of organ sparing strategies to treat penile cancer (PC) is currently supported by evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still represents up to 15-20% of primary tumor treatments in PC patients. The aim of the study was to evaluate efficacy in terms of overall survival (OS) and disease-free survival (DFS) of radical penectomy in PC patients.
• Harb-De la Rosa, A., Bracamonte, E., Chipollini, J., & Gretzer, M. (2020). A Rare Case of Urethral Schwannoma. Urology, 145, e1-e3.
• Harb-De la Rosa, A., Garcia-Castaneda, J., Hsu, C. H., Zeng, J., Batai, K., Lee, B. R., & Chipollini, J. (2020). Perioperative outcomes of open vs. robotic radical cystectomy: a nationwide comparative analysis (2008-2014). Central European journal of urology, 73(4), 427-431.
  More info

  Radical cystectomy (RC) is a complex procedure with high perioperative morbidity. In an effort to reduce complications, robotic-assisted RC (RARC) has been adopted as a minimally invasive alternative to the open approach (ORC). Herein, we examine post-operative outcomes of the two surgical approaches in the United States (US) using a large all-payer database.
• Lee, B. R., Gachupine, F. C., Chipollini, J., Batai, K., & Asmar, S. (2020). Abstract 1179: Renal cell carcinoma health disparities in American Indians Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry data. Epidemiology, 80(16_Supplement), 1179-1179. doi:10.1158/1538-7445.am2020-1179
• Peyton, C. C., Abel, E. J., Chipollini, J., Boulware, D. C., Azizi, M., Karam, J. A., Margulis, V., Master, V. A., Matin, S. F., Raman, J. D., Sexton, W. J., Wood, C. G., & Spiess, P. E. (2020). The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.. European urology focus, 6(1), 104-111. doi:10.1016/j.euf.2018.08.023
  More info

  The neutrophil-lymphocyte ratio (NLR) is an established signature of inflammation used for evaluating renal cell carcinoma (RCC)..To determine the utility of NLR and its relationship with known risk factors associated with poor survival in patients with metastatic RCC and tumor thrombus undergoing cytoreductive nephrectomy (CN)..Prognostic variables were reviewed for patients undergoing CN with thrombectomy between 2000 and 2014 from six different institutions. Patients were stratified for NLR >4.0 based on cut point analysis..Kaplan-Meier curves compared overall survival of the total cohort and established risk models (Memorial Sloan Kettering Cancer Center [MSKCC], International Metastatic Renal-Cell Carcinoma Database Consortium [IMDC], and M.D. Anderson Cancer Center [MDACC]) stratified by NLR. Multivariable Cox regression determined predictors of overall survival. Receiver operator characteristic curves tested the predictive accuracy of survival ≥12 mo, and area under the curve (AUC) was compared between models..In total, 332 patients were identified. Patients with NLR ≤4.0 had longer median survival (24.7 vs 15.2 mo, p=0.004). NLR >4.0 distinguished patients with significantly shorter survival for non-poor-risk groups defined by MSKCC, IMDC, and MDACC criteria. Systemic symptoms, low hemoglobin, elevated lactate dehydrogenase, retroperitoneal adenopathy, level IV thrombus, elevated absolute neutrophil count, and NLR >4 were independent predictors of decreased survival (p4.0 independently predicts poor survival and further distinguishes established risk model survival curves. We identified seven preoperative risk factors related to poor survival for patients with metastatic RCC with tumor thrombus undergoing CN..The neutrophil-lymphocyte ratio and six additional preoperative variables can be used to better council patients regarding survival after surgery for metastatic renal cell carcinoma with tumor thrombus.
• Peyton, C. C., Hajiran, A., Morgan, K., Azizi, M., Tang, D., Chipollini, J., Gilbert, S. M., Poch, M., Sexton, W. J., & Spiess, P. E. (2020). Urinary leak following partial nephrectomy: a contemporary review of 975 cases. The Canadian journal of urology, 27(1), 10118-10124.
  More info

  To describe the incidence, contemporary management, risk factors and outcomes of urinary leak following open and robotic partial nephrectomy at a tertiary care, comprehensive cancer center.
• Pollock, G. R., Meiklejohn, K. M., Zeng, J., & Chipollini, J. (2020). Robotic Cystoprostatectomy With Intracorporeal Ileal Conduit Diversion in a Patient With Chronic Schistosomiasis. Urology, 141, e8-e9.
  More info

  We present an interesting case of a patient who initially presented with urinary retention and was subsequently found to have bilateral grade 5 vesicoureteral reflux, a thick and noncompliant bladder, and biopsy proven ova of Schistosoma haematobium. This patient was subsequently managed surgically with a robotic radical cystoprostatectomy with intracorporeal ileal conduit diversion. Final pathology revealed chronic schistosomiasis with numerous ova present throughout the bladder. To our knowledge, no similar cases have been previously documented in the literature.
• Roussel, E., Peeters, E., Vanthoor, J., Bozzini, G., Muneer, A., Ayres, B., Sri, D., Watkin, N., Bhattar, R., Parnham, A., Sangar, V., Lau, M., Joice, G., Bivalacqua, T. J., Chipollini, J., Spiess, P. E., Hatzichristodoulou, G., de Vries, L., Brouwer, O., , Albersen, M., et al. (2020). Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma?. BJU international.
  More info

  To identify predictive pathological factors for local recurrence (LR) and to study the impact of LR on survival in patients treated with glansectomy for penile squamous cell carcinoma (pSCC).
• Zeng, J., Pollock*, G., Pollock, G. R., & Chipollini, J. (2020). MP23-01 NATIONAL TRENDS IN THE MANAGEMENT OF LOW RISK PROSTATE CANCER: ANALYZING THE IMPACT OF MEDICAID EXPANSION IN THE UNITED STATES. The Journal of Urology, 203(Supplement 4). doi:10.1097/ju.0000000000000856.01
  More info

  INTRODUCTION AND OBJECTIVE:We evaluated recent trends in the management of low risk prostate cancer (PCa) in the United States (US). Since little is known on factors affecting treatment patterns in...
• Zeng, J., Wong, A., Pollock, G., & Chipollini, J. (2020). Clinical evaluation of COVID-19/SARS-CoV-2 diagnostic testing in asymptomatic urology patients: implications for resumption of elective surgical care. World journal of urology.
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Marandino, L., Heidenreich, A., Hakenberg, O. W., Haidl, F., Chipollini, J., Briganti, A., Bandini, M., Azizi, M., Albersen, M., & Ager, M. (2020). Treatment patterns and outcomes of patients with penile squamous-cell carcinoma (PSCC) undergoing inguinal lymph node dissection (ILND): An analysis of a multicenter contemporary database.. Journal of Clinical Oncology, 38(15_suppl), 5585-5585. doi:10.1200/jco.2020.38.15_suppl.5585
  More info

  5585Background: PSCC is a rare tumor and the administration of guidelines-based therapies is still problematic in real-world practice. Survival outcomes remain suboptimal in patients (pts) with ILN...
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Marandino, L., Heidenreich, A., Hakenberg, O. W., Haidl, F., Chipollini, J., Catanzaro, M., Brower, O. R., Briganti, A., Bandini*, M., Bandini, M., , Azizi, M., et al. (2020). MP11-08 DEVELOPMENT OF A RISK CALCULATOR OF RECURRENCE IN INGUINAL LYMPH-NODE METASTATIC (ILNM) PATIENTS WITH SURGICALLY-RESECTED PENILE SQUAMOUS-CELL CARCINOMA (PSCC). The Journal of Urology, 203, e138. doi:10.1097/ju.0000000000000831.08
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Marandino, L., Heidenreich, A., Hakenberg, O. W., Haidl, F., Giannatempo, P., Chipollini, J., Briganti, A., Bandini, M., Azizi, M., Albersen, M., & Ager, M. (2020). Impact of human papillomavirus (HPV) infection on the outcome of perioperative treatments for penile squamous-cell carcinoma (PSCC).. Journal of Clinical Oncology, 38(15_suppl), 5088-5088. doi:10.1200/jco.2020.38.15_suppl.5088
  More info

  5088Background: PSCC patients (pts) with palpable inguinal lymph node (ILN) disease have a poor overall survival (OS). Multimodal perioperative treatments are usually offered despite the lack of cl...
• Zhu, Y., Ye, D., Watkin, N., Spiess, P. E., Raggi, D., Pederzoli, F., Ornellas, A. A., Necchi, A., Montorsi, F., Mazzone, E., Marandino, L., Heidenreich, A., Hakenberg, O. W., Haidl, F., Chipollini, J., Catanzaro, M., Brower, O. R., Briganti, A., Bandini*, M., , Bandini, M., et al. (2020). MP11-09 REGRESSION-TREE ANALYSIS FOR IDENTIFYING THE BEST CANDIDATES TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL NODE-POSITIVE PENILE SQUAMOUS-CELL CARCINOMA. The Journal of Urology, 203, e138. doi:10.1097/ju.0000000000000831.09
• Azizi, M., Boulware, D. C., Cheriyan, S. K., Peyton, C. C., Vullo, S. L., Mariani, L., Zhu, Y., Ye, D., Watkin, N., Ager, M., Raggi, D., Catanzaro, M., Salvioni, R., Chipollini, J., Gilbert, S. M., Necchi, A., Spiess, P. E., Ornellas, A. A., Hakenberg, O. W., & Azizi*, M. (2019). MP49-10 PROGNOSTICATORS OF INGUINAL LYMPH NODE METASTASIS AND SURVIVAL IN CLINICAL NODE-NEGATIVE PENILE SQUAMOUS CELL CARCINOMA PATIENTS. The Journal of Urology, 201(Supplement 4). doi:10.1097/01.ju.0000556488.97321.02
  More info

  INTRODUCTION AND OBJECTIVES:The main prognostic factors for survival among patients with penile squamous cell carcinoma (PSCC) remain the presence and the extent of lymph node metastasis (LNM). Kno...
• Azizi, M., Chipollini, J., Peyton, C. C., Cheriyan, S. K., & Spiess, P. E. (2019). Current controversies and developments on the role of lymphadenectomy for penile cancer.. Urologic oncology, 37(3), 201-208. doi:10.1016/j.urolonc.2018.08.017
  More info

  Penile squamous cell carcinoma is a rare cancer in men. The main prognosticators of survival for penile cancer patients remain the presence and the extent of lymph node metastasis. While radical inguinal lymphadenectomy has been the cornerstone of regional lymph node management for many years, it is still associated with significant morbidity and psychological distress. Recent developments in penile squamous cell carcinoma management have been met with some controversy in the urologic oncology community. Herein, we review the current controversies and developments on the role of inguinal lymphadenectomy for penile cancer.
• Azizi, M., Peyton, C. C., Boulware, D. C., Chipollini, J., Juwono, T., Pow-sang, J. M., & Spiess, P. E. (2019). Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.. European urology focus, 5(6), 1085-1090. doi:10.1016/j.euf.2018.06.008
  More info

  Further biomarkers are warranted to improve prognostic stratification of penile squamous cell carcinoma (PSCC) patients undergoing inguinal lymph node dissection (ILND)..To assess the prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in PSCC patients undergoing ILND and to investigate its role in predicting pathologic node-positive (pN+) disease..In total, 84 consecutive patients undergoing ILND for PSCC at our institution between 1994 and 2014 were identified. Sixty-eight patients with a complete blood count and differential prior to surgery were included. Median follow-up was 35.5 mo..Cut-off point analysis of NLR was performed using the Contal and O'Quigley method. Estimates of overall survival (OS), cancer-specific survival, and recurrence-free survival stratified by NLR were provided by the Kaplan-Meier method. Cox regression models were performed to determine predictors of survival and recurrence. Logistic regression models were used to identify factors associated with pathologic node-positivity..The cut-off point value was determined to be 3. Median OS was significantly shorter for patients with NLR ≥3 than those with NLR
• Azizi, M., Tang, D. H., Verduzco, D., Peyton, C. C., Chipollini, J., Yuan, Z., Schaible, B. J., Zhou, J., Johnstone, P. A., Dhillon, J., Spiess, P. E., & Giuliano, A. R. (2019). Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.. Clinical genitourinary cancer, 17(1), e80-e91. doi:10.1016/j.clgc.2018.09.012
  More info

  To assess the prognostic value of PI3K-AKT-mTOR signaling pathway up-regulation in a contemporary cohort of penile squamous-cell carcinoma (PSCC) patients..Tissue microarrays were constructed for 57 patients with invasive PSCC treated at our institution between 2000 and 2013. Immunohistochemical staining was performed for PTEN, AKT, and S6. Human papillomavirus (HPV) in-situ hybridization for high-risk subtypes was also performed. Biomarker expression was evaluated by a semiquantitative H score. Overall survival, disease-specific survival and recurrence-free survival stratified by biomarker expression (low vs. high) were estimated by the Kaplan-Meier method. Multivariable Cox regression models were used to determine predictors of mortality and recurrence..HPV in-situ hybridization was positive in 23 patients (40%). PTEN was down-regulated in 43 patients (75%), while phosphorylated-AKT (p-AKT) and phosphorylated-S6 (p-S6) were up-regulated in 27 (47%) and 12 patients (21%), respectively. In multivariable Cox regression models, patients with low expression of p-AKT had an increased risk of recurrence (hazard ratio [HR] = 3.95; 95% confidence interval [CI], 1.47-10.59; P = .02), while those with low expression of p-S6 had an increased risk of overall mortality (HR = 6.15; 95% CI, 1.55-24.36; P = .01). HPV status was an independent predictor of overall survival (HR = 6.99; 95% CI, 2.42-20.16; P < .001) and disease-specific survival (HR = 6.74; 95% CI, 2.02-22.48; P = .002)..PI3K-AKT-mTOR signaling pathway up-regulation and HPV coinfection in PSCC are associated with favorable disease. mTOR pathway biomarkers along with HPV status may represent novel prognosticators for risk stratification of PSCC patients and may help guide treatment decisions and follow-up strategies. These findings require further investigation.
• Batai, K., Harb-De la Rosa, A., Zeng, J., Chipollini, J. J., Gachupin, F. C., & Lee, B. R. (2019). Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes. Cancer medicine, 8(15), 6780-6788.
  More info

  Racial/ethnic minority groups have a higher burden of renal cell carcinoma (RCC), but RCC among Hispanic Americans (HAs) and American Indians and Alaska Natives (AIs/ANs) are clinically not well characterized. We explored variations in age at diagnosis and frequencies of RCC histologic subtypes across racial/ethnic groups and Hispanic subgroups using National Cancer Database (NCDB) and Arizona Cancer Registry Data.
• Chipollini, J. J., Batai, K., Harb‐De la Rosa, A., Zeng, J., Gachupin, F. C., & Lee, B. R. (2019). Racial/ethnic disparities in renal cell carcinoma: Increased risk of early‐onset and variation in histologic subtypes. Cancer Medicine, 8(15), 6780-6788. doi:10.1002/cam4.2552
• Chipollini, J., & Azizi, M. (2019). Clinical considerations of penile cutaneous lesions. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 13(2 Suppl 1), S1.
• Chipollini, J., Azizi, M., Lo Vullo, S., Mariani, L., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O., Heidenreich, A., Raggi, D., Catanzaro, M., Ornellas, P., Salvioni, R., Cheriyan, S. K., Necchi, A., & Spiess, P. E. (2019). Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU International, 125(1), 82-88. doi:10.1111/bju.14883
• Chipollini, J., De la Rosa, A. H., Azizi, M., Shayegan, B., Zorn, K. C., & Spiess, P. E. (2019). Patient presentation, differential diagnosis, and management of penile lesions. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 13(2 Suppl 1), S2-S8.
• Chipollini, J., Garcia-Castaneda, J., Harb-De la Rosa, A., Cheriyan, S., Azizi, M., & Spiess, P. E. (2019). Important surgical concepts and techniques in inguinal lymph node dissection. Current opinion in urology, 29(3), 286-292.
  More info

  Penile cancer is a rare disease with significant physical and psychosocial morbidity. It has a propensity to spread to the inguinal lymph nodes where it can progress to the pelvis and beyond. Here, we present a contemporary review on the surgical management of the lymph nodes.
• Chipollini, J., Tang, D. H., Reich, R. R., Leone, A. R., Gilbert, S. M., Sexton, W. J., & Zhou, J. (2019). Trends in Insurance Status during Initial Presentation of Testicular Carcinoma: Examining Health Outcomes and Implications of Health Reform for Young Adults in the United States. Urology Practice, 6(1), 18-23. doi:10.1016/j.urpr.2018.02.005
  More info

  AbstractIntroduction:We evaluated trends in insurance status, and assessed socioeconomic factors associated with clinically metastatic testicular cancer presentation and potential barriers to treat...
• Chipollini, J., da Costa, W. H., Werneck da Cunha, I., de Almeida e Paula, F., Guilherme O. Salles, P., Azizi, M., Spiess, P. E., Abreu, D., & Zequi, S. d. (2019). Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Therapeutic Advances in Urology, 11, 175628721988260. doi:10.1177/1756287219882600
• Lwin, A. A., Hsu, C. H., & Chipollini, J. (2019). Urothelial Carcinoma of the Renal Pelvis and Ureter: Does Location Make a Difference?. Clinical genitourinary cancer.
  More info

  There is a paucity of data on outcomes of upper tract urothelial carcinoma (UTUC) arising from the renal pelvis (RPUC) versus UTUC arising from the ureter (UUC). The published literature is conflicting, and there is no consensus on patient prognosis based on disease location. The aim of this study is to compare clinical and survival outcomes based on location of primary tumor using a large national registry.
• Lwin, A. A., Pollock, G. R., & Chipollini, J. (2019). Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-trends and effect on overall survival. Annals of translational medicine, 7(Suppl 6), S196.
• Necchi, A., Lo Vullo, S., Mariani, L., Zhu, Y., Ye, D. W., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O. W., Heidenreich, A., Raggi, D., Catanzaro, M., Salvioni, R., Chipollini, J., Azizi, M., & Spiess, P. E. (2019). Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urologic oncology, 37(8), 531.e7-531.e15.
  More info

  To improve the prognostic allocation of patients with penile squamous-cell carcinoma (PSCC) receiving regional lymph node dissection (LND).
• Necchi, A., Mariani, L., Zhu, Y., Ye, D., Ornellas, A. A., Watkin, N., Ager, M., Hakenberg, O. W., Heidenreich, A., Raggi, D., Catanzaro, M., Salvioni, R., Chipollini, J., Azizi, M., Spiess, P. E., & Vullo, S. L. (2019). Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy.. Journal of Clinical Oncology, 37(7_suppl), 512-512. doi:10.1200/jco.2019.37.7_suppl.512
  More info

  512Background: Advances in prognostic allocation of pts with PSCC receiving regional LND are needed, along with an assessment of the role of perioperative treatments. Methods: An international, mul...
• Necchi, A., Mariani, L., Zhu, Y., Ye, D., Watkin, N., Ager, M., Heidenreich, A., Raggi, D., Catanzaro, M., Salvioni, R., Chipollini, J., Azizi, M., Vullo, S. L., Spiess, P. E., Ornellas, A. A., & Hakenberg, O. W. (2019). Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy. European Urology Supplements, 18(1), e648. doi:10.1016/s1569-9056(19)30478-6
• Veccia, A., Varga, J., Tracey, A., Tema, G., Spiess, P. E., Sountoulides, P., Schips, L., Olarte, J. Q., Nyirady, P., Nunzio, C. D., Musi, G., Micali, S., Lima, M. V., Guruli, G., Ditonno, P., Diogenes, E., Conti, A., Cobelli, O. D., Cindolo, L., , Chipollini, J. J., et al. (2019). Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World Journal of Urology, 37(8), 1649-1657. doi:10.1007/s00345-018-2549-3
  More info

  We aimed to evaluate adherence to the EAU guidelines (GL) on penile cancer (PC) with regard to primary surgical treatment and management of lymph nodes and to estimate the influence of adherence to GL on clinical outcome. This is a retrospective multicenter study (PEnile Cancer ADherence study, PECAD Study) on PC patients treated at 12 European and American centers between 2010 and 2016. Adherence to the EAU GL on the surgical management of the primary penile tumor and lymphadenectomy was evaluated. Descriptive analyses were performed, and survival curves were estimated. Data on 425 patients were considered for the analysis. The EAU GL on surgical treatment of the primary tumor and lymphadenectomy were respected in 74.8% and 73.7% of cases, respectively. Survival analysis showed that adherence to the GL on primary penile surgery was significantly associated with a good overall survival [adjusted HR 0.40 (95% CI 0.20–0.83, p value = 0.014)]. Also, the adherence to the GL on lymphadenectomy was statistically significantly associated with overall survival [adjusted HR 0.48 (95% CI 0.24–0.96, p value = 0.038)]. Limited follow-up and retrospective design represent limitations of this study. Our findings suggest that there is a good adherence to the EAU GL on PC. However, this should be further reinforced, endorsed and encouraged as it might translate into better clinical outcomes for PC patients.
• Zeng, J., Harb-De la Rosa, A., & Chipollini, J. (2019). Current landscape of cytoreductive nephrectomy: who, when, and why?. Annals of translational medicine, 7(Suppl 3), S77.
• Abel, J., Chipollini, J., Boulware, D., Azizi, M., Margulis, V., Zargar-shoshtari, K., Wood, C. P., Spiess, P. E., Sexton, W. J., Raman, J. D., Peyton, C. C., Matin, S. F., Master, V. A., & Karam, J. A. (2018). MP66-15 THE PROGNOSTIC VALUE OF NEUTROPHIL-LYMPHOCYTE RATIO FOR METASTATIC RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY: A MULTI-INSTITUTION CONSORTIUM ANALYSIS. The Journal of Urology, 199(4S). doi:10.1016/j.juro.2018.02.1887
• Azizi, M., Chipollini, J., Peyton, C. C., Cheriyan, S. K., & Spiess, P. E. (2018). Current controversies and developments on the role of lymphadenectomy for penile cancer. Urologic oncology.
  More info

  Penile squamous cell carcinoma is a rare cancer in men. The main prognosticators of survival for penile cancer patients remain the presence and the extent of lymph node metastasis. While radical inguinal lymphadenectomy has been the cornerstone of regional lymph node management for many years, it is still associated with significant morbidity and psychological distress. Recent developments in penile squamous cell carcinoma management have been met with some controversy in the urologic oncology community. Herein, we review the current controversies and developments on the role of inguinal lymphadenectomy for penile cancer.
• Azizi, M., Peyton, C. C., Boulware, D. C., Chipollini, J., Juwono, T., Pow-Sang, J. M., & Spiess, P. E. (2018). Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection. European urology focus.
  More info

  Further biomarkers are warranted to improve prognostic stratification of penile squamous cell carcinoma (PSCC) patients undergoing inguinal lymph node dissection (ILND).
• Azizi, M., Tang, D. H., Verduzco, D., Chipollini, J., Peyton, C. C., Zhou, J., Schaible, B., Dhillon, J., & Spiess, P. E. (2018). MP37-15 PI3K-AKT-MTOR PATHWAY IN PENILE SQUAMOUS CELL CARCINOMA: CLINICAL SIGNIFICANCE OF PTEN, AKT AND S6 EXPRESSION. The Journal of Urology, 199(4S). doi:10.1016/j.juro.2018.02.1221
• Azizi, M., Tang, D. H., Verduzco, D., Peyton, C. C., Chipollini, J., Yuan, Z., Schaible, B. J., Zhou, J. M., Johnstone, P. A., Giuliano, A., Dhillon, J., & Spiess, P. E. (2018). Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature. Clinical genitourinary cancer.
  More info

  To assess the prognostic value of PI3K-AKT-mTOR signaling pathway up-regulation in a contemporary cohort of penile squamous-cell carcinoma (PSCC) patients.
• Baumgarten, A., Chipollini, J., Yan, S., Ottenhof, S. R., Tang, D. H., Draeger, D., Protzel, C., Zhu, Y., Ye, D. W., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. E. (2018). Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. The Journal of urology, 199(5), 1233-1237.
  More info

  We evaluated recurrence outcomes of penile sparing surgery in what is to our knowledge the largest multicenter cohort of patients to date.
• Baumgarten, A., Chipollini, J., Yan, S., Ottenhof, S. R., Tang, D. H., Draeger, D., Protzel, C., Zhu, Y., Ye, D., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. (2018). Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort.. Journal of Urology, 199(5), 1233-1237. doi:https://doi.org/10.1016/j.juro.2017.10.045
• Chipollini, J., & Pow-Sang, J. M. (2018). Lymph node positive prostate cancer: the evolving role of adjuvant therapy. Translational Cancer Research, 7(1). doi:10.21037/tcr.2018.01.33
  More info

  For decades, lymph node metastasis (LNM) at the time of radical prostatectomy (RP) has been considered as a poor prognostic sign. Currently, the appropriate timing for androgen deprivation therapy (ADT) remains controversial. Only one small prospective randomized study (ECOG 3886) has shown improved survival for immediate vs. delayed ADT in this select group of patients
• Chipollini, J., Abel, E. J., Peyton, C. C., Boulware, D. C., Karam, J. A., Margulis, V., Master, V. A., Zargar-Shoshtari, K., Matin, S. F., Sexton, W. J., Raman, J. D., Wood, C. G., & Spiess, P. E. (2018). Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clinical genitourinary cancer, 16(2), e443-e450.
  More info

  To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma.
• Chipollini, J., Abel, E. J., Peyton, C. C., Boulware, D. C., Karam, J. A., Margulis, V., Master, V. A., Zargar-Shoshtari, K., Matin, S. F., Sexton, W. J., Raman, J. D., Wood, C. G., & Spiess, P. E. (2018). Pathologic predictors of survival during lymph node dissection for metastatic renal cell carcinoma: Results from a multicenter collaboration. Clinical Genitorurinary Cancer, 16(2). doi:https://doi.org/10.1016/j.clgc.2017.10.004
• Chipollini, J., Alford, B., Boulware, D. C., Forget, P., Gilbert, S. M., Lockhart, J. L., Pow-Sang, J. M., Sexton, W. J., Spiess, P. E., Poch, M. A., & Patel, S. Y. (2018). Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC anesthesiology, 18(1), 157.
  More info

  The perioperative period can be a critical period with long-term implications on cancer-related outcomes. In this study, we evaluate the influence of regional anesthesia on cancer-specific outcomes in a radical cystectomy (RC) cohort of patients.
• Chipollini, J., Azizi, M., Fishman, M., Zhang, J., Tang, D. H., Spiess, P. E., Sexton, W. J., Reich, R. R., Pow-sang, J. M., Poch, M. A., Peyton, C. C., Manley, B. J., & Gilbert, S. M. (2018). PD11-10 NEOADJUVANT DOSE-DENSE MVAC INCREASES DOWN-STAGING AND IMPROVES SURVIVAL COMPARED TO OTHER CHEMOTHERAPY REGIMENS. The Journal of Urology, 199(4). doi:10.1016/j.juro.2018.02.633
• Chipollini, J., Azizi, M., Peyton, C. C., Tang, D. H., Dhillon, J., & Spiess, P. E. (2018). Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. Journal of kidney cancer and VHL, 5(4), 6-13.
  More info

  The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan-Meier method. Median age was 58 years and median follow-up was 40 months. Non-ccRCC subtypes included sarcomatoid ( = 9), rhabdoid ( = 6), medullary ( = 2), Xp11.2 translocation ( = 2), collecting duct ( = 1), papillary type I ( = 11), and papillary type II ( = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of non-ccRCC cases and was associated with adverse histopathologic features. Expression of biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions and follow-up strategies.
• Chipollini, J., Necchi, A., & Spiess, P. E. (2018). Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. European urology, 74(2), 241-242.
• Chipollini, J., Tang, D. H., Manimala, N., Gilbert, S. M., Pow-Sang, J. M., Sexton, W. J., Poch, M. A., & Spiess, P. E. (2018). Evaluating the Accuracy of Intraoperative Frozen Section during Inguinal Lymph Node Dissection for Penile Cancer. Urologic Oncology, 36(1). doi:https://doi.org/10.1016/j.urolonc.2017.08.018
• Chipollini, J., Tang, D. H., Manimala, N., Gilbert, S. M., Pow-Sang, J. M., Sexton, W. J., Poch, M. A., & Spiess, P. E. (2018). Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urologic oncology, 36(1), 14.e1-14.e5.
  More info

  Inguinal lymph node dissection is an integral part in the management of invasive penile tumors with intraoperative assessment often aiding decision-making during dissection. In this study, we evaluate the diagnostic value of intraoperative frozen section (FS) and analyze clinicopathologic factors that affect its accuracy.
• Chipollini, J., Tang, D. H., Sharma, P., & Spiess, P. E. (2018). National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window. Clinical genitourinary cancer, 16(2), e383-e389.
  More info

  The purpose of this study was to analyze contemporary trends and predictors in the use of organ-sparing treatment (OST) for low-stage invasive penile tumors as well as to ascertain its impact on overall mortality (OM) in those with high-risk (pT2) disease.
• Chipollini, J., Yan, S., Ottenhof, S. R., Zhu, Y., Draeger, D., Baumgarten, A. S., Tang, D. H., Protzel, C., Ye, D. W., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. E. (2018). Surgical management of penile carcinoma in situ: results from an international collaborative study and review of the literature. BJU international, 121(3), 393-398.
  More info

  To evaluate recurrence after penile-sparing surgery (PSS) in the management of carcinoma in situ (CIS) of the penis in a large multicentre cohort of patients.
• Cindolo, L., Bada, M., Nyirady, P., Varga, J., Chipollini, J., Ditonno, P., Battaglia, M., Chiodini, P., Tema, G., Veccia, A., Antonelli, A., Musi, G., Conti, A., Micali, S., Diogenes, E., Valima, M., Tracey, A., Guruli, G., Autorino, R., , Schips, L., et al. (2018). The adherence to the EAU Guidelines dramatically influences the survival of patients with penile cancer: Result from a retrospective international study (PECAD Study). European Urology Supplements, 17(2), e38-e39. doi:10.1016/s1569-9056(18)30879-0
• Cindolo, L., Spiess, P. E., Bada, M., Chipollini, J. J., Nyirády, P., Chiodini, P., Varga, J., Ditonno, P., Battaglia, M., De Nunzio, C., Tema, G., Veccia, A., Antonelli, A., Musi, G., De Cobelli, O., Conti, A., Micali, S., Maestro, M. A., Olarte, J. Q., , Diogenes, E., et al. (2018). Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World journal of urology.
  More info

  We aimed to evaluate adherence to the EAU guidelines (GL) on penile cancer (PC) with regard to primary surgical treatment and management of lymph nodes and to estimate the influence of adherence to GL on clinical outcome.
• Ghahhari, J., Cindolo, L., Chipollini, J., Nyirady, P., Chiodini, P., Varga, J., Ditonno, P., Battaglia, M., Tema, G., Veccia, A., Antonelli, A., Musi, G., Conti, A., Micali, S., Tracey, A., Autorino, R., Sountoulides, P., Bada, M., Marchioni, M., , Schips, L., et al. (2018). Total penectomy, a compromise for life: Results from the pecad study. European Urology Supplements, 17(8), 173-174. doi:10.1016/s1569-9056(18)33056-2
• Peyton, C. C., Abel, E. J., Chipollini, J., Boulware, D. C., Azizi, M., Karam, J. A., Margulis, V., Master, V. A., Matin, S. F., Raman, J. D., Sexton, W. J., Wood, C. G., & Spiess, P. E. (2018). The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. European urology focus.
  More info

  The neutrophil-lymphocyte ratio (NLR) is an established signature of inflammation used for evaluating renal cell carcinoma (RCC).
• Peyton, C. C., Azizi, M., Chipollini, J., Ercole, C., Fishman, M., Gilbert, S. M., Juwono, T., Lockhart, J., Poch, M., Pow-Sang, J. M., Spiess, P. E., Wiegand, L., & Sexton, W. J. (2018). Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clinical genitourinary cancer, 16(5), e1003-e1013.
  More info

  Primary urethral carcinoma (PUC) is rare, and standard treatment recommendations are lacking. We examined the variation in treatments and survival outcomes of female PUC at a single, tertiary referral cancer center.
• Peyton, C. C., Tang, D., Reich, R. R., Azizi, M., Chipollini, J., Pow-Sang, J. M., Manley, B., Spiess, P. E., Poch, M. A., Sexton, W. J., Fishman, M., Zhang, J., & Gilbert, S. M. (2018). Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA oncology.
  More info

  Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with cystectomy alone for patients with bladder cancer. Although gemcitabine with cisplatin has become a standard NAC regimen, a dose-dense combination of methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) is being adopted at some institutions.
• Peyton, C., Azizi, M., Chipollini, J., Ercole, C., Fishman, M., Gilbert, S., Juwono, T., Lockhart, J., Poch, M., Pow-Sang, J., Spiess, P., Wiegand, L., & Sexton, W. (2018). Survival Outcomes Associated with Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clinical Genitourinary Cancer. Clinical Genitourinary Cancer. doi:https://doi.org/10.1016/j.clgc.2018.05.012
• Russell, C. M., Lebastchi, A. H., Chipollini, J., Niemann, A., Mehra, R., Morgan, T. M., Miller, D. C., Palapattu, G. S., Hafez, K. S., Sexton, W. J., Spiess, P. E., & Weizer, A. Z. (2018). Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. Urology, 117, 95-100.
  More info

  To evaluate whether incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) for clinical T1 disease results in inferior oncologic outcomes compared to pT1a-b disease.
• Tang, D. H., Chipollini, J., & Spiess, P. E. (2018). Postchemotherapy lymph node dissection for isolated retroperitoneal nodal recurrences for penile cancer: Is cure possible in highly selected cases?. Urologic oncology, 36(1), 1-3.
  More info

  Outcomes for advanced penile carcinoma remain poor with limited options for curative treatment. Nodal recurrences represent worse prognosis and are typically treated with a combination of radiation, chemotherapy, or consolidative resection. Although the ideal management for recurrences remains unknown, there is some evidence supporting the role of chemotherapy followed by consolidative resection. Using a multimodal strategy, we describe the curative potential of postchemotherapy retroperitoneal lymph node dissection for penile cancer patients with isolated locoregional recurrences in the retroperitoneum.
• Tang, D. H., Yan, S., Ottenhof, S. R., Draeger, D., Baumgarten, A. S., Chipollini, J., Protzel, C., Zhu, Y., Ye, D. W., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. E. (2018). Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urologic oncology, 36(4), 147-152.
  More info

  Although the trend towards penile sparing therapy is increasing for penile squamous cell carcinoma, outcomes for laser ablation therapy have not been widely reported. We assessed the clinical outcomes of penile cancer patients treated with only laser ablation.
• Chipollini, J. J., Tang, D. H., Patel, S. Y., Garcia-Getting, R. E., Gilbert, S. M., Pow-Sang, J. M., Sexton, W. J., Spiess, P. E., & Poch, M. A. (2017). Author Reply. Urology, 103, 148.
• Chipollini, J. J., Tang, D. H., Patel, S. Y., Garcia-Getting, R. E., Gilbert, S. M., Pow-Sang, J. M., Sexton, W. J., Spiess, P. E., & Poch, M. A. (2017). Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology, 103, 142-148.
  More info

  To evaluate the effect of leukoreduced-only perioperative blood transfusion (PBT) and corresponding survival outcomes in a radical cystectomy cohort of patients.
• Chipollini, J., Chaing, S., Azizi, M., Kidd, L. C., Kim, P., & Spiess, P. E. (2017). Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets. International journal of molecular sciences, 18(8).
  More info

  Penile cancer (PeCa) is a rare malignancy with potentially devastating effects. Squamous cell carcinoma is the most common variant with distinct precancerous lesions before development into invasive disease. Involvement of the inguinal lymph nodes is the most important prognostic factor in PeCa, and once disease is present outside the groin, prognosis is poor. Metastatic PeCa is challenging to treat and often requires multidisciplinary approaches in management. Due to its rarity, molecular understanding of the disease continues to be limited with most studies based on small, single center series. Thus far, it appears PeCa has diverse mechanisms of carcinogenesis affecting similar molecular pathways. In this review, we evaluate the current landscape of the molecular carcinogenesis of PeCa and explore ongoing research on potential actionable targets of therapy. The emergence of anti-epidermal growth factor receptor (EGFR) and other immunotherapeutic strategies may improve outcomes for PeCa patients.
• Chipollini, J., Chaing, S., Peyton, C. C., Sharma, P., Kidd, L. C., Giuliano, A. R., Johnstone, P. A., & Spiess, P. E. (2017). National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012). Clinical genitourinary cancer.
  More info

  We analyzed the trends in presentation of squamous cell carcinoma (SCC) of the penis and determined the socioeconomic predictors for locally advanced (cT3-cT4) disease in the United States.
• Chipollini, J., Hussein, K., Tang, D. H., Poch, M. A., Patel, S. Y., & Getting, R. E. (2017). MP32-16 COST IMPACT ANALYSIS OF ENHANCED RECOVERY AFTER SURGERY PROTOCOL IMPLEMENTATION IN A RADICAL CYSTECTOMY COHORT OF PATIENTS. The Journal of Urology, 197(4). doi:10.1016/j.juro.2017.02.991
• Chipollini, J., Tang, D. H., Gilbert, S. M., Poch, M. A., Pow-Sang, J. M., Sexton, W. J., & Spiess, P. E. (2017). Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. The Journal of urology, 198(6), 1346-1352.
  More info

  To our knowledge it is unknown whether concomitant inguinal lymph node dissection at the time of penectomy improves outcomes in patients with penile cancer. We analyzed predictors of regional recurrence as well as disease specific survival based on time of inguinal lymph node dissection. We also determined an optimal time to perform inguinal lymph node dissection.
• Chipollini, J., Tang, D. H., Hussein, K., Patel, S. Y., Garcia-Getting, R. E., Pow-Sang, J. M., Gilbert, S. M., Sexton, W. J., Spiess, P. E., & Poch, M. A. (2017). Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology, 105, 108-112.
  More info

  To compare perioperative charges induced at the initial phase of a standardized enhanced recovery after surgery (ERAS) program from a tertiary referral center.
• Chipollini, J., Tang, D. H., Sharma, P., Baumgarten, A. S., & Spiess, P. E. (2017). Patterns of Regional Lymphadenectomy for Clinically Node-negative Patients With Penile Carcinoma: Analysis From the National Cancer Database From 1998 to 2012. Clinical genitourinary cancer, 15(6), 670-677.e1.
  More info

  Evidence supports upfront regional lymphadenectomy (rND) when primary penile tumors exhibit high-risk features and negative inguinal adenopathy (cN0). We sought to analyze trends in the utilization of early rND as well as assess factors associated with its use and survival outcomes using a nationwide cancer registry database.
• Chipollini, J., Yan, S., Ottenhof, S., Zhu, Y., Ye, D., Protzel, C., Horenblas, S., Watkin, N. A., Tang, D. H., Spiess, P. E., & Baumgarten, A. S. (2017). PD49-04 ONCOLOGICAL OUTCOMES AND PATTERNS OF RECURRENCE OF PENILE SPARING APPROACHES FOR CARCINOMA OF THE PENIS: A RETROSPECTIVE, MULTICENTER COHORT ANALYSIS. The Journal of Urology, 197(4). doi:10.1016/j.juro.2017.02.2228
• Jordan, A. R., Lokeshwar, S. D., Lopez, L. E., Hennig, M., Chipollini, J., Yates, T., Hupe, M. C., Merseburger, A. S., Shiedlin, A., Cerwinka, W. H., Liu, K., & Lokeshwar, V. B. (2017). Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget, 8(15), 24262-24274.
  More info

  Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides). AGF support tumor growth and progression. Urine and tissue HAase/HYAL-1 levels are sensitive markers for high-grade bladder cancer (BCa) and its metastasis. In preclinical models of BCa, we evaluated whether o-sulfated AGF (sHA-F) inhibits HAase activity and has antitumor activity. At IC50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P
• Kidd, L. C., Chaing, S., Chipollini, J., Giuliano, A. R., Spiess, P. E., & Sharma, P. (2017). Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Translational andrology and urology, 6(5), 791-802.
  More info

  Penile cancer is a rare disease in the United States, but rates are increasing, causing concern. Several risk factors have been associated with the disease, including human papillomavirus (HPV) infection. Knowledge of HPV pathogenesis has led to the development of a vaccine, which has proven instrumental in reducing the incidence of female HPV-related cancers, but results in men have yet to be elucidated. Fortunately, rates of vaccination are up-trending in both males and females in the past several years. In addition, targeted therapies are the focus of several ongoing research efforts. Some of these therapeutics are currently in use, while several are in trials. With continued patient education and research, both treatment and prevention of HPV-related pre-malignant lesions and penile cancer will likely diminish.
• Kidd, L., Chaing, S., Chipollini, J., Giuliano, A., Spiess, P., & Sharma, P. (2017). Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. Translational Andrology and Urology (TAU), 6(5), 791-802. doi:10.21037/tau.2017.06.27
• Leone, A., Chipollini, J., Henriksen, C., Tang, D. H., Sexton, W. J., Poch, M. A., Gilbert, S. M., & Crispen, P. L. (2017). MP69-13 PATIENT REPORTED HEALTH AND QUALITY OF LIFE AFTER NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY: RESULTS FROM BLADDER CANCER OUTCOMES AND IMPACT STUDY. The Journal of Urology, 197(4). doi:10.1016/j.juro.2017.02.2309
• Russell, C. M., Lebastchi, A. H., Chipollini, J., Mehra, R., Morgan, T. M., Miller, D. C., Palapattu, G. S., Hafez, K. S., Wolf, J. S., Sexton, W. J., Spiess, P. E., Weizer, A. Z., & Niemann, A. C. (2017). MP72-06 MULTI-INSTITUTIONAL SURVIVAL ANALYSIS OF INCIDENTAL PATHOLOGIC T3A UPSTAGING IN CLINICAL T1 RENAL CELL CARCINOMA FOLLOWING PARTIAL NEPHRECTOMY. The Journal of Urology, 197(4), 95-100. doi:10.1016/j.juro.2017.02.2242
  More info

  OBJECTIVE To evaluate whether incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) for clinical T1 disease results in inferior oncologic outcomes compared to pT1a-b disease. MATERIALS AND METHODS Retrospective chart review was completed at the University of Michigan and Moffitt Cancer Center to identify patients undergoing PN for clinical T1 masses between 1995 and 2015. A total of 1955 patients were identified, of which 95 had pT3a upstaging. Median follow-up was 38.2 months. Patients with pT3a disease were individually matched by clinicopathologic features with patients undergoing PN with pT1a-b disease in a 1:2 ratio. Kaplan-Meier analysis and univariate and multivariable Cox proportional hazards regression analysis were performed. Primary endpoint was recurrence-free survival (RFS). Secondary endpoints were all-cause mortality, cancer-specific survival (CSS), and rates of local and distant recurrence. RESULTS Recurrence rates were significantly higher in pT3a disease compared to pT1a-b controls (P 
• Tang, D. H., Djajadiningrat, R., Diorio, G., Chipollini, J., Ma, Z., Schaible, B. J., Catanzaro, M., Ye, D., Zhu, Y., Nicolai, N., Horenblas, S., Johnstone, P. A., & Spiess, P. E. (2017). Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urologic oncology, 35(10), 605.e17-605.e23.
  More info

  Few studies have examined the role of radiation therapy in advanced penile squamous cell carcinoma. We sought to evaluate the association of adjuvant pelvic radiation with survival and recurrence for patients with penile cancer and positive pelvic lymph nodes (PLNs) after lymph node dissection.
• Tang, D. H., Nawlo, J., Chipollini, J., Gilbert, S. M., Poch, M., Pow-Sang, J. M., Sexton, W. J., & Spiess, P. E. (2017). Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clinical genitourinary cancer, 15(6), 696-703.
  More info

  We reviewed the outcomes for an octogenarian population to investigate whether active surveillance (AS) provides comparable survival to partial nephrectomy (PN) or radical nephrectomy (RN).
• Tang, D. H., Yan, S., Ottenhof, S. R., Draeger, D., Baumgarten, A. S., Chipollini, J., Protzel, C., Zhu, Y., Ye, D. W., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. E. (2017). Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology, 109, 140-144.
  More info

  To analyze the recurrence and survival outcomes of glansectomy in patients with penile squamous cell carcinoma.
• Chipollini, J., & Ciancio, G. (2016). Renal Cell Carcinoma Invading Duodenum: Management by Pancreaticoduodenectomy and Discussion of Treatments. Journal of Gastrointestinal and Digestive System, 6(2). doi:10.4172/2161-069x.1000394
  More info

  At present, complete surgical resection remains the standard for curative intervention in cases of locally advanced renal cell carcinoma (RCC) although the role of surgery in cases of adjacent visceral invasion remains controversial. We report a case of a right sided RCC involving the duodenum and head of pancreas in which en-bloc resection was achieved by radical nephrectomy and concomitant pancreaticoduodenectomy. For those patients with good performance status, aggressive interventions should be thoroughly discussed along with the role of targeted systemic therapies in the adjuvant setting.
• Hennig, M. J., Lokeshwar, S. D., Wilson, S. N., Jordan, A. R., Chipollini, J., Hupe, M. C., Kramer, M. W., Lopez, L. E., Merseburger, A. S., & Lokeshwar, V. B. (2016). MP61-01 ANTITUMOR ACTIVITY OF SULFATED ANGIOGENIC FRAGMENTS: A NOVEL HYALURONIDASE INHIBITOR. The Journal of Urology, 195(4). doi:10.1016/j.juro.2016.02.875
• Hennig, M., Jordan, A., Chipollini, J., Lopez, L., Merseburger, A. S., Lokeshwar, V. B., Kramer, M. W., & Hupe, M. C. (2016). 289 Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer. European Urology Supplements, 15(3), e289. doi:10.1016/s1569-9056(16)60291-9
• Chipollini, J., Tang, D., Sharma, P., & Spiess, P. (2017). National trends and predictors of organ-sparing for invasive penile tumors: Expanding the therapeutic window. Clinical Genitourinary Cancer, 16(2). doi:10.1016/j.clgc.2017.09.004
• Chipollini, J., Yan, S., Ottenhof, S. R., Zhu, Y., Draeger, D., Baumgarten, A. S., Tang, D. H., protzel, C., Ye, D., Hakenberg, O. W., Horenblas, S., Watkin, N. A., & Spiess, P. E. (2017). Surgical management of penile carcinoma-in-situ: Lessons learned from an international study collaboration and review of the literature.. British Journal of Urology International. doi:https://doi.org/10.1111/bju.14037
  More info

  To evaluate recurrence after penile‐sparing surgery (PSS) in the management of carcinoma in situ (CIS) of the penis in a large multicentre cohort of patients.
• Chipollini, J., Yates, T., Racine, R. R., Lopez, L. E., Lokeshwar, V. B., & Lokeshwar, S. D. (2015). MP45-03 TARGETING OF BIOMARKERS OF BLADDER CANCER METASTASIS BY 4-METHYLUMBELLIFERONE. The Journal of Urology, 193(4). doi:10.1016/j.juro.2015.02.1501
  More info

  INTRODUCTION AND OBJECTIVES: Hyaluyronic acid (HA) and HYAL-1 hyaluronidase family of molecules are potential markers for BCa diagnosis and predicting prognosis and promote tumor growth and metastasis. 4-Methylumbelliferone (4-MU) is an orally bioavailable dietary supplement that inhibits HA synthesis. Epithelial mesenchymal transition (EMT) is the hallmark of invasion and metastasis. Since HA promotes tumor metastasis and EMT, we evaluated the expression of EMT markers in bladder tissues and antitumor effects of 4-MU in BCa models. METHODS: Quantitative PCR was used to measure mRNA expression of EMT genes (B-catenin, Twist, and Snail) in 66 bladder tissue specimens (27 normal; 39 tumor); follow-up: 26þ/-4.3 months; median 20 months. The effect of 4-MU (40 e 120 mg/ml) on cell proliferation, apoptosis, intracellular signaling, and the expression of HA receptors, and EMT genes were examined in BCa cell lines, 253J-Lung and HT1376. HA addition and mAkt overexpression were conducted to delineate the mechanism of action of 4-MU. Effect of 4-MU on tumor growth was analyzed in subcutaneous xenografts. RESULTS: Among the EMT genes, Snail and Twist were differentially expressed in BCa tissues when compared to normal bladder (P 3-fold) when treatment was started either on the day of tumor cell injection or after tumors became palpable. No weight loss or serum or organ toxicity was observed in treated mice. CONCLUSIONS: This study shows that expression of EMT determinants correlates with clinical outcome. Furthermore, the nontoxic dietary supplement 4-MU has potent antitumor activity and reverses EMT.
• Jordan, A. R., Jordan, A. R., Chipollini, J., Chipollini, J., Yates, T., Yates, T., Lopez, L. E., Lopez, L. E., Lokeshwar, V. B., & Lokeshwar, V. B. (2015). Abstract 2647: Anti-tumor activity of sHA8k, a HYAL1 hyaluronidase inhibitor, in bladder cancer cells. Cancer Research, 75, 2647-2647. doi:10.1158/1538-7445.am2015-2647
  More info

  INTRODUCTION AND OBJECTIVE: Tumor cell-derived hyaluronidase HYAL1, which degrades hyaluronic acid (HA) into angiogenic fragments, promotes tumor growth and metastasis. HYAL-1 is an independent prognostic marker for predicting metastasis. Small molecular mass sulfated hyaluronic acid (sHA) derivatives (sHA8k) inhibit HYAL1 activity through a mixed inhibition mechanism. Antitumor activity of sHA8k and mechanism of action was evaluated in BCa models.. METHODS: Effect of sHA8k (0-40 ug/ml) on cell proliferation and apoptosis was examined in BCa cells (253J-Lung, HT1376, UMUC-3, T24, RT4) by cell counting and Cell Death ELISA kit. Matrigel invasion and Boyden chamber assays were used to test the effect of sHA8k on invasive activity. Effect of sHA on signaling, apoptosis cascade, HA receptor (CD44, RHAMM), EMT markers (β-catenin, E-cadherin, Snail, Twist) levels, was evaluated by Q-pCR and immunoblotting assays. Angiogenic fragment addition and mAkt transfection were performed to elucidate mechanism of action. Athymic mice bearing 253J-Lung xenografts were treated with sHA (25 and 50 mg/kg) by i.p. injection. RESULTS: sHA8k inhibited proliferation, motility and invasion in BCa cells that expressed HYAL-1. At IC50 for HAase activity inhibition (∼ 20-μg/ml), sHA induced > 3-fold apoptosis and inhibited invasive activity of BCa cells. sHA8k induced caspase-3, -8, -9 activation, up-regulation of Fas, Fas-L, FADD, DR4, DR5 and E-cadherin. sHA8k downregulated CD44, RHAMM, bcl-2, phospho(p)-Akt, pGSK3β, pβcatenin(ser552), snail and Twist expression. Effect of sHA8k were attenuated by angiogenic HA fragments or overexpression of m-Akt and downregulation of CD44 and RHAMM mimicked sHA8k effects. sHA significantly inhibited 253J-Lung xenograft growth. The majority of the animals did not form palpable tumors at 50-mg/kg dose. No weight loss or serum and organ toxicity was observed in sHA treated animals. Biochemical analysis of tumors also showed the same alterations in Akt and EMT pathways as observed cell culture. CONCLUSION: This is the first study that shows sHA8k, a small molecular mass HYAL-1 inhibitor has potent antitumor activity. Support: R01 CA 72821-14 (VBL) Citation Format: Andre R. Jordan, Juan Chipollini, Luis Lopez, Travis Yates, Vinata Lokeshwar. Anti-tumor activity of sHA8k, a HYAL1 hyaluronidase inhibitor, in bladder cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2647. doi:10.1158/1538-7445.AM2015-2647
• Peyton, C. C., Chipollini, J., Azizi, M., Kamat, A. M., Gilbert, S. M., & Spiess, P. E. (2019). Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World journal of urology, V. 37, Issue 10, pp 2017–2029.
  More info

  Intravesical therapy has been an important aspect of the management of non-muscle invasive bladder cancer (NMIBC) for 40 years. Bacillus Calmette-Guerin (BCG) is considered standard of care for intermediate and high-grade non-invasive disease, yet understanding the nuances of subsequent intravesical therapy is important for any provider managing bladder cancer. Herein, we review the literature and describe optimal use of intravesical therapies for NMIBC.
• Canon, S., Mosley, B., Chipollini, J., Purifoy, J. A., & Hobbs, C. (2012). Epidemiological assessment of hypospadias by degree of severity. The Journal of urology, 188(6), 2362-6.
  More info

  Hypospadias is one of the most common congenital malformations, with reportedly increasing rates of prevalence but poorly defined etiological factors for the disease and the varying degrees of manifestation. We characterize the prevalence of hypospadias in Arkansas with consideration of the degree of hypospadias.
• Canon, S., Chipollini, J., Purifoy, J., Mosley, B. S., & Hobbs, C. A. (2011). 252 Hypospadias on the Rise in Arkansas: Epidemiologic Assessment. The Journal of Urology, 185(4). doi:10.1016/j.juro.2011.02.343
• Greathouse, D., Vostrikov, V., McClellan, N., Chipollini, J., Lay, J., Liyanage, R., & Ladd, T. (2018). Lipid interactions of acylated tryptophan-methylated lactoferricin peptides by solid-state NMR. Journal of peptide science : an official publication of the European Peptide Society, 14(10), 1103-10.
  More info

  Lactoferricin (LfB) is a 25-residue innate immunity peptide released by pepsin from the N-terminal region of bovine lactoferrin. A smaller amidated peptide, LfB6 (RRWQWR-NH2) retains antimicrobial activity and is thought to constitute the "antimicrobial active-site" (Tomita, Acta Paediatr Jpn. 1994; 36: 585-91). Here we report on N-acylation of 1-Me-Trp5-LfB6, Cn-RRWQ[1-Me-W]R-NH2, where Cn is an acyl chain having n = 0, 2, 4, 6 or 12 carbons. Tryptophan 5 (Trp5) was methylated to enhance membrane binding and to allow for selective deuteration at that position. Peptide/lipid interactions of Cn-RRWQ[1-Me-W]R-NH2 (deuterated 1-Me-Trp5 underlined), were monitored by solid state 31P NMR and 2H NMR. The samples consisted of macroscopically oriented bilayers of mixed neutral (dimyristoylphosphatidylcholine, DMPC) and anionic (dimyristoylphosphatidylglycerol, DMPG) lipids in a 3:1 ratio with Cn-RRWQ[&1-Me-W]R-NH2 peptides added at a 1:25 peptide to lipid ratio. 2H-NMR spectra reveal that the acylated peptides are well aligned in DMPC:DMPG bilayers. The 2H NMR quadrupolar splittings suggest that the 1-Me-Trp is located in a motionally restricted environment, indicating partial alignment at the membrane interface. 31P-NMR spectra reveal that the lipids are predominantly in a bilayer configuration, with little perturbation by the peptides. Methylation alone, in C0-RRWQ[1-Me-W]R-NH2, resulted in a 3-4 fold increase in antimicrobial activity against E. coli. N-acylation with a C12 fatty acid enhanced activity almost 90 fold.
• Mcclellan, N., Chipollini, J., Liyanage, R., Ladd, T., Vostrikov, V. V., Lay, J. O., & Greathouse, D. V. (2008). Lipid interactions of acylated tryptophan-methylated lactoferricin peptides by solid-state NMR.. Journal of peptide science : an official publication of the European Peptide Society, 14(10), 1103-10. doi:10.1002/psc.1047
  More info

  Lactoferricin (LfB) is a 25-residue innate immunity peptide released by pepsin from the N-terminal region of bovine lactoferrin. A smaller amidated peptide, LfB6 (RRWQWR-NH2) retains antimicrobial activity and is thought to constitute the "antimicrobial active-site" (Tomita, Acta Paediatr Jpn. 1994; 36: 585-91). Here we report on N-acylation of 1-Me-Trp5-LfB6, Cn-RRWQ[1-Me-W]R-NH2, where Cn is an acyl chain having n = 0, 2, 4, 6 or 12 carbons. Tryptophan 5 (Trp5) was methylated to enhance membrane binding and to allow for selective deuteration at that position. Peptide/lipid interactions of Cn-RRWQ[1-Me-W]R-NH2 (deuterated 1-Me-Trp5 underlined), were monitored by solid state 31P NMR and 2H NMR. The samples consisted of macroscopically oriented bilayers of mixed neutral (dimyristoylphosphatidylcholine, DMPC) and anionic (dimyristoylphosphatidylglycerol, DMPG) lipids in a 3:1 ratio with Cn-RRWQ[&1-Me-W]R-NH2 peptides added at a 1:25 peptide to lipid ratio. 2H-NMR spectra reveal that the acylated peptides are well aligned in DMPC:DMPG bilayers. The 2H NMR quadrupolar splittings suggest that the 1-Me-Trp is located in a motionally restricted environment, indicating partial alignment at the membrane interface. 31P-NMR spectra reveal that the lipids are predominantly in a bilayer configuration, with little perturbation by the peptides. Methylation alone, in C0-RRWQ[1-Me-W]R-NH2, resulted in a 3-4 fold increase in antimicrobial activity against E. coli. N-acylation with a C12 fatty acid enhanced activity almost 90 fold.

Presentations

• Batai, K., Asif, W., Wightman, P., Cruz, A., Valencia, C. I., Gachupin, F. C., Hsu, P., Chipollini, J., & Lee, B. R. (2022, September). Intersectionality of neighborhood social deprivation, race/ethnicity, and obesity in renal cell carcinoma disparities. . American Association for Cancer Research Conference. Philadelphia, PA: American Association for Cancer Research.
• Zeng, J., Funk, J., Lee, B. R., Hsu, C., Messing, E., & Chipollini, J. (2022, Fall). Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: Results from a tertiary center in the contemporary BCG-shortage era .. Western Section American Urological Association.
• Chipollini, J. (2021). Kidneys and Cancer: Public Health Implications.. WebinarConsulate of Mexico in Tucson.
  More info

  Offered for viewing on YouTube and Facebook
• Cruz, A., Dickerman, F., Pulling, K. R., Garcia, K., Gachupin, F. C., Hsu, C. H., Chipollini, J., Lee, B. R., & Batai, K. (2021, October). Impacts of neighborhood characteristics and surgical treatment disparities on overall mortality in Stage I renal cell carcinoma patients. . The 14th AACR Conference on the Science of Cancer Health Disparities in Racial/ethnic Minorities and the Medically Underserved.. Virtual Conference: American Association of Cancer Research.
• Lee, B. R., Chipollini, J., Gachupin, F. C., Hsu, C. H., Pulling, K. R., Cruz, A., & Batai, K. (2022, Spring).

  Renal Cell Carcinoma Surgical Treatment Disparities in Hispanic Americans.

  . American Society of Preventive Oncology.
• Zeng, J., Wong, A., Pollock, G., & Chipollini, J. (2020, Fall). Clinical Evaluation of COVID-19/SARS-CoV-2 Diagnostic Testing In Asymptomatic Urology Patients: Implications For Resumption Of Elective Surgical Care. Western Section American Urological Association.
• Chipollini, J. (2019, Fall). Characterization of urinary microbiome in patients with bladder cancer: Results from a pilot feasibility study. . Western Section AUA 95th Annual Conference.
• Chipollini, J., Faraj, K. S., Rose, K. M., Navaratnam, A. K., Abdul-Muhsin, H. M., Eversman, S., Richards, J., Singh, V., Cheney, S. M., Tyson, M. D., & Castle, E. P. (2019, November). Characterization of Urinary Microbiome in Patients with Bladder Cancer: Results From a Pilot Feasibility Study.. BLADDER/TESTIS/URETHRA - Western Section American Urological Association. Monterey, CA: Western Section American Urological Association.

Poster Presentations

• Garcia, K., Zeng, J., Recio Boiles, A., Heimark, R. L., & Chipollini, J. (2022, Fall). Prostate cancer presentation in Hispanic Americans: a nationwide comparative analysis of Hispanic Americans versus non-Hispanic whites. Western Section American Urological Association.
• Zeng, J., Paster, I. C., Recio Boiles, A., & Chipollini, J. (2022, Fall). Gender, racial and ethnic differences in pathologic response following neoadjuvant chemotherapy for baldder cancer patients.. Western Section American Urological Association.
• Batai, K., Quinonez-Zanabira, E., Asif, W., Wong, A. C., Cruz, A., Gachupin, F. C., Hsu, C., Chipollini, J., & Lee, B. R. (2021, Fall). Impact of Preoperative Wait time on Tumor Characteristics and Racial and Ethnic Disparities. American Urological Association.
• Pollock, G., & Chipollini, J. (2021, Fall). National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status. American Urological Association.
• Batai, K., Pollock, G., Gachupin, F. C., Chipollini, J., & Lee, B. R. (2020, May). Assessment of Renal Cell Carcinoma Surgical Disparities in American Indians and Hispanic Americans. American Urological Association Annual Meeting. Washington, DC: American Urological Association.
• Chipollini, J. (2020, Fall). Gemcitabine for the treatment of high-risk non-muscle invasive bladder cancer: Results of safety and early efficacy from a single institution’s bladder cancer program in the BCG-shortage era. Western Section American Urological Association.
• Lee, B. R., Chipollini, J., Gachupin, F. C., Asmar, S., & Batai, K. (2020, April). Renal cell carcinoma health disparities in American Indians Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry data. American Association for Cancer Research Annual Meeting. Virtual: American Association for Cancer Research.
• Pollock, G., de Vries, H., Slongo, J., Boyd, F., Spiess, P., & Chipollini, J. (2020, Fall). Outcomes of Perineal Urethrostomy for Penile Cancer: A 20-year International Multicenter Experience.. Western Section American Urological Association.
• Chipollini, J., & Pollock, G. (2019, November 2019). National Trends In the Management of Low Risk Prostate Cancer: Analyzing The impact of Medicaid Expansion In The United States.. Moderated Poster Session, Annual Western Section, American Urological Association. Monterey, CA: Western Section, American Urological Association.
• Chipollini, J., Wright, J., Nwanosike, H., Kepler, C., Batai, K., Lee, B., Stewart, D., & Lamendella, R. (2019, December). Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study. Poster Presentation - Society of Urologic Oncology, Inc.. Washington, D.C.: Society of Urologic Oncology, Inc..
• Pollock, G., & Chipollini, J. (2019, December). National trends in the Management of Low Risk Prostate Cancer: Analyzing the impact of Medicaid expansion in the United States. Poster Presentation - Society of Urologic Oncology. Washington, D.C.: Society of Urologic Oncology.
• Pollock, G., Zeng, J., & Chipollini, J. (2019, November). Opioid Sparing Enhanced Recovery After Surgery Cystectomy Protocol: Minimizing Complications.. Unmoderated Poster Session, Western Section, American Urological Association. Monterey, CA: Western Section, American Urological Association.
• Zeng, J., Hsu, C., & Chipollini, J. (2019, Novermber). Trends in Gastrointestinal Recovery After Radical Cystectomy: A Nationwide Analysis in the Enhanced Recovery Era.. Unmoderated Poster Session, Western Section, American Urological Association. Monterey, CA: Western Section, American Urological Association.